https://trial.medpath.com/news/3509e1e9c8cf4ed1/medicare-names-first-10-drugs-for-price-negotiations-including-major-diabetes-and-cancer-therapies 2023-08-29T05:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/8845c3e502bc96ee/bluerock-s-phase-i-study-with-bemdaneprocel-in-parkinson-s-disease-meets-primary-endpoint 2023-08-28T10:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/e573031c13d431b7/merck-launches-first-phase-3-program-for-oral-pcsk9-inhibitor-mk-0616-to-treat-high-cholesterol 2023-08-25T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/87e2e947d49e065c/synapticure-on-science-clinical-trials-for-sporadic-als 2023-08-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a4f32bc021ccdef9/lipid-nanoparticles-demonstrate-complex-immunological-effects-in-mrna-vaccine-delivery 2023-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/31a9d3c0cdfd2dbb/ai-revolution-in-pharma-transforming-drug-development-to-patient-care 2023-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8d13d36519cfe07e/genesis-therapeutics-secures-200m-series-b-to-advance-ai-powered-drug-discovery-platform 2023-08-21T12:46:52+00:00 weekly 0.7 https://trial.medpath.com/news/ea4987a8bbbdb6bf/study-protocol-of-the-launch-3-trial-comparing-laparoscopic-and-abdominal-radical-hysterectomy-for-cervical-cancer 2023-08-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1a9cb82a47e224df/yale-researchers-develop-polymer-nanoparticles-for-effective-mrna-delivery-to-lungs 2023-08-16T19:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/9d573ed52c38c7e3/lupin-receives-fda-approval-for-generic-bromfenac-ophthalmic-solution-for-post-cataract-surgery-treatment 2023-08-16T15:43:00+00:00 weekly 0.7 https://trial.medpath.com/news/a7412f2681135532/phase-3-clear-study-shows-improved-efficacy-of-lenvatinib-plus-pembrolizumab-in-advanced-renal-cell-carcinoma 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1b460f40e532209f/european-commission-approves-second-line-axi-cel-for-dlbcl-hgbl-onclive 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d7f31734779d781f/immix-announces-additional-nxc-201-al-amyloidosis-data-to-be-presented-tipranks-com 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5d30c25a1aa8bf12/european-regulators-recommend-cabometyx-for-radioactive-iodine-refractory-thyroid-cancer-based-on-78-reduction-in-disease-progression 2023-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d5045f664f15e338/acelyrin-inc-reports-second-quarter-2023-financial 2023-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0c062ba86ca0891d/xeltis-axess-vascular-graft-development-receives-funding-from-european 2023-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/311fee6aafa2d778/weight-loss-drug-wegovy-cuts-heart-attack-risk-in-people-with-obesity-study-shows 2023-08-08T19:04:51+00:00 weekly 0.7 https://trial.medpath.com/news/5e14b968f17e647c/asco-s-guideline-rapid-recommendation-update-for-esr1-mutation-testing 2023-08-08T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/416c64d17d06f7bb/first-veteran-receives-fda-approved-qalsody-for-sod1-als-at-houston-va-medical-center 2023-08-07T14:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/26f0f24d62b3ed7e/jacobio-pharma-announces-breakthrough-therapy-designation-pr-newswire 2023-08-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f0c994f2d3d61673/fda-approves-avacincaptad-pegol-for-geographic-atrophy 2023-08-05T14:10:38+00:00 weekly 0.7 https://trial.medpath.com/news/a64d93d9f94f1cf9/fda-approves-an-oral-treatment-for-postpartum-depression-called-zuranolone 2023-08-05T11:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/6a0469beaafc7b09/ugn-102-may-be-an-effective-non-surgical-option-for-bladder-cancer-subtype 2023-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/35a8095cbe3759de/targeting-the-endothelin-a-receptor-in-iga-nephropathy-a-new-therapeutic-approach 2023-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9e6500f579e71669/cage-bio-announces-positive-topline-results-from-its-phase-2-study-on-tofacitinib-for-atopic-dermatitis 2023-08-03T14:46:08+00:00 weekly 0.7 https://trial.medpath.com/news/e60aed1e3d68ca70/new-treatment-could-ease-symptoms-of-children-with-adhd-wales-online 2023-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0cb10a1fe2aab9e7/actuate-therapeutics-receives-fda-orphan-drug 2023-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1fa4c6172686ce12/obexelimab-shows-promise-in-treating-igg4-related-disease 2023-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9e69c9a7d63ff7f8/tyra-biosciences-announces-fda-orphan-drug-designation-for-tyra-300-for 2023-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3ba785fcb0c8830b/ai-cancer-detection-tool-shows-13-boost-in-prostate-cancer-diagnosis-expands-to-breast-cancer-screening-in-wales 2023-07-31T00:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/ac700f7c71bd7749/first-long-covid-treatment-clinical-trials-from-nih-getting-underway-cbs-news 2023-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/12c38b3ca15f12db/advancements-in-hcc-treatment-the-role-of-tace-combined-with-targeted-and-immune-therapies 2023-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/deb4b9937715e465/artificial-intelligence-enhances-diagnostic-accuracy-in-capsule-endoscopy-for-small-bowel-bleeding 2023-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e3b74adb88488b9d/safety-and-efficacy-of-ak0529-in-respiratory-syncytial-virus-infected-infant-patients 2023-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0394d61ad296034e/applied-therapeutics-provides-regulatory-update-on-galactosemia-program 2023-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/87e38ab649dd1df3/samuraciclib-shows-promise-in-advanced-breast-cancer-patients-after-cdk4-6-inhibitor-failure 2023-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dfa6b91085c010a6/update-on-rapamycin-clinical-trial-for-pc-treatment 2023-07-21T18:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/3c7ed7073bde3634/digital-transformation-reshapes-pharma-industry-with-30b-investment-drive 2023-07-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/02ca955f6d1e94d1/roche-s-vabysmo-shows-sustained-vision-improvements-with-extended-treatment-intervals-in-retinal-vein-occlusion-studies 2023-07-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a3cfa6cccf339afd/lucas-was-facing-life-in-a-wheelchair-until-a-medical-trial-gave-his-parents-hope-abc-news 2023-07-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dd99d83b8c7cb8a4/mind-diet-may-not-be-brain-boosting-in-the-short-term-new-clinical-trial-shows-cnn 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d0350085237b293e/fda-accepts-nda-for-rivoceranib-camrelizumab-in-unresectable-hcc 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b2787fac2f8ae8e/magic-mushrooms-could-help-women-deal-with-cancer-related-depression-world-news-sky-news 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a83bd857e4213cdf/new-study-finds-alzheimers-drug-donanemab-can-modestly-slow-memory-decline-the-new-york-times 2023-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8e41c582e0d691c0/long-term-follow-up-data-reinforce-efficacy-of-pembrolizumab-based-combinations-in-advanced-renal-cell-carcinoma 2023-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/552a808253f914af/polyunsaturated-fats-and-als-disease-progression-cap-1002-improves-motor-function-in-dmd-lecanemab-granted-traditional-approval 2023-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/542be6df443704b6/experts-forecast-major-shifts-in-lung-cancer-treatment-immunotherapy-and-precision-medicine-lead-the-way 2023-07-13T04:44:53+00:00 weekly 0.7 https://trial.medpath.com/news/7b4bfa56be9e812a/pirtobrutinib-shows-promising-efficacy-in-cll-sll-patients-after-btk-inhibitor-failure 2023-07-12T14:00:22+00:00 weekly 0.7 https://trial.medpath.com/news/200adc8b19ffd49b/dfd-29-bests-competition-for-papulopustular-rosacea-in-adults-practicaldermatology 2023-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/09a90f2101d8bac4/first-u-s-patients-implanted-with-innovative-fire1-remote-heart 2023-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0345f08446771852/biophytis-receives-fda-authorization-for-first-ever-phase-3-sarcopenia-trial 2023-07-10T11:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/05568e75f745de4b/tango-therapeutics-initiates-phase-1-2-trial-of-tng462-for-mtap-deleted-solid-tumors 2023-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/079efed1bb6c4126/fda-widens-door-to-research-on-psychedelics-like-ketamine-lsd-for-treatment-of-ptsd-depression-los-angeles-times 2023-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a9b6f288584ae663/cell-therapy-cap-1002-continues-to-show-preservation-of-cardiac-function-in-open-label-extension-study-of-dmd 2023-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e95b6e94e3c9388c/digital-care-program-shows-comparable-effectiveness-to-in-person-physiotherapy-for-chronic-low-back-pain 2023-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a9a2a1f40aff4cd1/sulopenem-etzadroxil-probenecid-drug-market-forecast-and-analysis-sulopenem-etzadroxil-probenecid-for-uncomplicated-urinary-tract-infection-market-size-analysis-and-competitive-landscape-by-delveinsight 2023-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b49439d00a7662a0/spectral-launches-three-new-trial-sites-for-hemoperfusion-device-trial 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/74c4296479e3414b/people-with-alzheimers-urged-to-follow-fiona-phillips-and-join-drug-trials-alzheimer-s-the-guardian 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7d9ffa0c45d27d4f/sequana-medical-achieves-milestone-with-1000th-alfapump-implant-advances-to-heart-failure-trial 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e200f93554f8ff0a/what-to-know-about-leqembi-the-alzheimers-drug-approved-by-the-fda-the-new-york-times 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cedf50a8a6207abb/i-mab-announces-publication-of-claudin18-2-x-4-1bb-biospace 2023-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7c37a9a9bee03413/margetuximab-an-active-alternative-for-later-line-therapy-in 2023-07-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0dfcfc47276e72f8/fda-s-dct-draft-guidance-a-hit-or-miss 2023-07-03T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eecef7f77c656261/evaluation-of-the-one-step-nucleic-acid-amplification-method-for-rapid-detection-of-lymph-node-metastases-in-endometrial-cancer 2023-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0ecdb82ce91fbf96/first-fully-ai-generated-drug-enters-phase-ii-clinical-trials-for-idiopathic-pulmonary-fibrosis 2023-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a0e4ad7e14ac3887/gene-therapy-approved-for-duchenne-muscular-dystrophy 2023-06-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e1f449632481c16e/biotech-stock-roundup-srpt-s-dmd-therapy-approval-icpt-s-setback-more-updates 2023-06-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/51455866f1a31711/hvivo-plc-develops-hmpv-human-challenge-model 2023-06-28T07:15:30+00:00 weekly 0.7 https://trial.medpath.com/news/f45f08dc47d38acc/abbvie-s-atogepant-shows-significant-efficacy-in-treatment-resistant-episodic-migraine-patients 2023-06-26T15:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/5155943f4fd9015c/janssen-submits-marketing-authorisation-application-to-the 2023-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0cd884a5a57d923e/stock-market-financialcontent-business-page 2023-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ec822f0b953197ef/approved-anti-obesity-medications-in-2022-a-comprehensive-overview 2023-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1f4e31edcbd08f10/moderna-submits-fda-application-for-updated-covid-19-vaccine-targeting-xbb-variants 2023-06-22T21:25:39+00:00 weekly 0.7 https://trial.medpath.com/news/3bd9b82dd0cec186/fda-approved-cancer-drug-ruxolitinib-shows-promise-for-treating-cardiac-arrhythmias 2023-06-22T17:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/7ad29b6814ea89af/zanubrutinib-plus-obinutuzumab-and-venetoclax-shows-high-undetectable-mrd-rate-in-cll-sll 2023-06-22T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/43a669108ae8fe78/navigating-complex-validation-challenges-in-atmp-analytical-methods-key-considerations-for-drug-development 2023-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/27a5cc0f45d8a411/sequana-medical-announces-positive-outcomes-from-north-american-pivotal-alfapump-study-poseidon 2023-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ed8f0e47bfc2cb32/emerging-role-of-glp-1-agonists-in-obesity 2023-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cadb491ac4c063db/anbalcabtagene-autoleucel-shows-84-response-rate-in-relapsed-refractory-large-b-cell-lymphoma 2023-06-20T20:26:53+00:00 weekly 0.7 https://trial.medpath.com/news/ee111ae5f49fcf9c/tiny-implant-has-been-proven-to-half-the-number-of-hospital-admissions-for-heart-failure-daily-mail-online 2023-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c83ff81a20e88e50/fda-delays-decision-on-gsk-bone-cancer-drug-acquired-in-2b-buyout 2023-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1a087a196d3dd2f0/fda-approves-avita-medical-s-recell-system-for-vitiligo-skin-repigmentation 2023-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ee221648786a9eda/4sc-ag-resminostat-marketing-application-proceeding-kinselby 2023-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/50fcb32c9ea306c6/olix-pharmaceuticals-initiates-phase-i-trial-for-androgenic-alopecia-treatment 2023-06-14T10:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/ed4e040cb91b0d8e/immix-biopharma-completes-5-million-at-the-market-equity-offering-program 2023-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/85f2d3e98ed98088/video-real-world-data-show-good-results-of-faricimab-in-dme-healio 2023-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/06792bfbb73c780c/astellas-faces-setback-as-us-court-invalidates-key-myrbetriq-patent 2023-06-12T03:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/f6738a12472cb9f7/perioperative-durvalumab-plus-chemotherapy-reduces-disease-progression-risk-by-32-in-resectable-nsclc 2023-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2870e4e551dcc4c/innovation-in-radionuclide-therapy-for-the-treatment 2023-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bb9978df7e42d091/selinexor-shows-significant-survival-benefits-in-multiple-myeloma-subgroups-from-boston-trial 2023-06-09T16:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/d4cd3fd0db186f84/crispr-gene-therapies-show-promise-in-early-sickle-cell-disease-trials 2023-06-09T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/989c78cf60516a9a/fda-advisers-vote-in-favor-of-infant-rsv-drug-time 2023-06-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d5875b51ede0d78/ai-revolutionizes-clinical-trials-three-key-innovations-transforming-patient-recruitment-and-retention 2023-06-07T23:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/f9fa36a8410079ed/frontiers-comparative-evaluation-of-clinical-glycemic-control-markers 2023-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4e702aa0f20953e4/brainchild-04-study-is-enrolling-patients-with-brain-and-spinal-cord 2023-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/21a90cf4d27e4ed1/merck-launches-constitutional-challenge-against-medicare-drug-price-negotiations 2023-06-06T09:56:26+00:00 weekly 0.7 https://trial.medpath.com/news/b1367bfcdaf5b9d3/a-subpopulation-analysis-of-the-phase-3-arasens-study 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2231e9b71e33c2ba/fda-prioritizes-gsk-s-breakthrough-drug-jemperli-for-endometrial-cancer-treatment-a-first-in-decades 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/751b6b1b251ed518/uromems-achieves-breakthrough-with-first-smart-artificial-urinary-sphincter-implant-in-female-patient 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/27b12745dd82d4fe/repare-therapeutics-atr-inhibitor-camonsertib-shows-promise-in-dna-repair-deficient-cancers 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/41b9b3d4b1afbd73/sensydia-secures-3m-nih-grant-to-advance-ai-based-cardiac-assessment-platform-biospace 2023-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7283a8da43963dad/avutometinib-defactinib-combination-shows-45-response-rate-in-low-grade-serous-ovarian-cancer 2023-06-04T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2d82628b3039ccd1/vorasidenib-shows-promise-as-first-targeted-therapy-for-idh-mutant-low-grade-gliomas 2023-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ec9865e8415346b4/u-s-tuberous-sclerosis-drug-market-projected-to-reach-1-25-billion-by-2030-growing-at-23-1-cagr 2023-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0aad30cee710d46a/sanofi-to-present-new-oncology-data-at-asco-2023 2023-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e2be39caf701654f/varmx-secures-eur30m-series-b2-funding-to-advance-anticoagulation-reversal-drug-vmx-c001-toward-pivotal-trial 2023-06-01T09:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/7a2414615dbad2eb/nfl-biosciences-nfl-101-shows-promise-as-first-in-class-smoking-cessation-treatment-in-phase-2-trial 2023-06-01T08:00:14+00:00 weekly 0.7 https://trial.medpath.com/news/d0569ef9a7eaac30/avacta-acquires-belgium-based-coris-bioconcept-for-ps7-4-million-to-expand-diagnostics-portfolio 2023-06-01T05:59:44+00:00 weekly 0.7 https://trial.medpath.com/news/bfbdf42056354843/clinical-trials-in-essential-thrombocythemia-et 2023-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fba270a1e931cd35/phase-1-2a-clinical-trial-in-als-with-ropinirole-a-drug 2023-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5150f01acb3c0ceb/metriopharm-s-mp1032-receives-fda-orphan-drug-designation-for-duchenne-muscular-dystrophy-treatment 2023-05-30T09:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/f156414291eebf3a/fda-approves-new-psma-targeted-pet-imaging-agent-for-prostate-cancer 2023-05-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ac01a13317f6ff67/sunlight-and-fresco-2-trials-show-promising-results-for-refractory-colorectal-cancer-treatment 2023-05-29T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5429194e7efdc49e/i-mab-reports-data-from-phase-ib-ii-nsclc-combo-therapy-trial 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ffaa8820b5aa2a14/update-on-the-efficacy-of-venetoclax-for-chronic-lymphocytic-leukemia 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2c4ea322675ddd9c/phase-iii-trial-explores-ribociclib-plus-endocrine-therapy-for-early-breast-cancer 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ee7055e3bb73d676/usda-approves-first-therapeutic-treatment-for-canine-parvovirus-using-monoclonal-antibody-technology 2023-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2d49ea697c744310/fda-approves-first-gene-therapy-for-rare-skin-disease-but-costs-are-outrageous-cbs-colorado 2023-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aefdab464f01280b/elon-musks-brain-implant-technology-gains-fda-approval-fox-business 2023-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/775c9524d92145e3/tvardi-therapeutics-to-present-phase-1-trial-data-of-stat3-inhibitor-tti-101-at-asco-2023 2023-05-25T09:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/5c9118b69cc9b7c4/bial-r-d-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of 2023-05-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bb46d067037bbaf2/vega-therapeutics-receives-fda-orphan-drug 2023-05-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/230878a65f6b7f5c/valbiotis-announces-success-of-reverse-it-clinical-study-on-totum-63 2023-05-22T17:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/c801aedbea239d77/microbiome-modulation-with-sim01-shows-promise-for-long-covid-treatment-in-randomized-trial 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/442a5a1fb260581a/heart-device-breakthrough-next-cochlear-stock-ebr-systems-surges-after-heart-device-breakthrough-surges-after-heart-device-breakthrough 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/400cb6394347ab93/study-highlights-delays-in-confirmatory-studies-for-accelerated-fda-approvals 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e1879bbeedc72b54/nexcella-announces-positive-nxc-201-clinical-results-at-asgct-100-overall-response-rate-in-darzalex-relapsed-refractory-al-amyloidosis-with-zero-icans-in-ongoing-nexicart-1-phase-1b-2a-clinical-trial-biospace 2023-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/514be95f898bd435/fda-approves-two-bispecific-t-cell-engagers-for-relapsed-refractory-b-cell-lymphomas 2023-05-19T17:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/61421c16d8167380/u-s-fda-approves-krystal-biotech-s-skin-disorder-gene-therapy 2023-05-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/86497e7945cc9947/ai-powered-clinical-trial-matching-platforms-show-promise-in-addressing-patient-recruitment-challenges 2023-05-18T02:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/e6f3f6ac01398245/satsuma-pharmaceuticals-announces-fda-acceptance-of-505-b-2-nda-for 2023-05-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b4f013bab3a46c8b/siren-biotechnology-unveils-promising-preclinical-data-for-novel-cancer-treatment-combining-aav-gene-therapy-with-cytokine-immunotherapy 2023-05-17T00:01:02+00:00 weekly 0.7 https://trial.medpath.com/news/78216c9aae60a07b/elevar-therapeutics-submits-new-drug-application-to-fda-for-combination 2023-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7dceaaf741baef3e/aging-dogs-provide-insights-for-human-longevity 2023-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/04e9070e6a670fb6/biophytis-receives-regulatory-approval-to-launch-first-ever-phase-3-trial-for-sarcopenia-treatment 2023-05-15T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fd89f0a80ba765c2/local-news-tailored-for-you-citybiz 2023-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/99884150f4eccb50/tucatinib-plus-trastuzumab-shows-promise-for-her2-positive-metastatic-colorectal-cancer 2023-05-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a61cdb3002ecf62d/skin-patch-developed-with-ucc-researchers-helps-ease-peanut-allergy-symptoms-in-toddlers-the-irish-times 2023-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/57a7784419c70f4e/skyrocketing-popularity-puts-glp-1-agonists-for-weight-loss-on-cardiologys-radar 2023-05-12T17:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/d938a69497661763/novo-holdings-leads-200m-series-a-investment-in-windward-bio-for-advanced-respiratory-treatments 2023-05-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/718282c3cf2f518d/mirocals-trial-results-low-dose-il-2-shows-potential-benefit-for-subset-of-mnd-patients 2023-05-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cf46bc960213e668/kintor-pharma-s-kx-826-shows-statistically-significant-hair-growth-in-us-phase-ii-trial-for-male-pattern-baldness 2023-05-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d1beafed101d98a3/adjuvant-atezolizumab-and-bevacizumab-delays-recurrence-in-early-stage-hcc 2023-05-10T19:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/4fa2e6cf8f3fa02c/fda-guidance-agenda-what-is-cder-cooking-for-clinical-trials 2023-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cc35fb53839da02f/paradigm-trial-highlights-egfr-targeting-therapy-benefits-for-metastatic-colorectal-cancer 2023-05-08T12:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/7310094c32271844/lorlatinib-shows-promise-in-alk-driven-refractory-neuroblastoma-with-emerging-resistance-mechanisms-identified 2023-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c9ce4e1aa8c98457/long-term-safety-and-efficacy-of-mesenchymal-stem-cell-therapy-in-severe-covid-19-patients 2023-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/461ee43fc019e392/breakthroughs-in-biotech-promising-developments-in-diabetes-cancer-and-lymphoma-treatments 2023-05-04T17:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/728bf51a874eb6b5/visus-therapeutics-announces-positive-phase-3-clinical-trial-results-for-brimocholtm-pf-in-treating-presbyopia 2023-05-04T12:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/3ae902fbd8f0e2ee/an-rsv-vaccine-has-been-approved-by-the-fda-its-a-huge-deal-vox 2023-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/657befe5c5a061c3/pharmaessentia-initiates-phase-3b-trial-of 2023-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/02a2c7b9680823e3/eli-lilly-trial-finds-alzheimers-drug-can-slow-progress-of-disease-the-new-york-times 2023-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/42021c6a7a9ffefa/j-j-expands-cell-therapy-portfolio-with-new-car-t-deals 2023-05-02T12:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/1e8502b160a0701e/lecanemab-in-early-alzheimer-s-disease 2023-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/45b8f89433dd65f3/experimental-brain-cancer-vaccine-survaxm-shows-promise-in-extending-glioblastoma-survival-to-26-months 2023-04-30T19:50:49+00:00 weekly 0.7 https://trial.medpath.com/news/5a58de760397fcbd/church-based-intervention-aims-to-reduce-blood-pressure-in-african-americans 2023-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/78c681527c5fe0ac/toripalimab-combo-shows-superior-survival-over-sunitinib-in-renal-cell-carcinoma 2023-04-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/46954132c27791df/iomt-set-to-transform-healthcare-with-486b-market-projection-by-2031 2023-04-28T02:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/fa87ce37243f52f9/ema-recommends-extension-of-indications-for-nivolumab 2023-04-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aa11aacd6bb9966d/eli-lilly-s-tirzepatide-shows-superior-weight-loss-results-in-diabetes-patients-fda-approval-expected-by-year-end 2023-04-27T21:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/a8676425be9b33a2/novel-bcma-targeted-therapies-and-emerging-agents-transform-treatment-landscape-for-relapsed-refractory-multiple-myeloma 2023-04-26T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/54da51568b015bc7/eu-unveils-ambitious-pharmaceutical-reform-single-market-plan-sparks-industry-debate 2023-04-26T06:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/f97c09b8b6e5034e/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study 2023-04-26T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/a85c0049eec72c7f/dual-action-hydrogel-prevents-brain-cancer-returning-in-100-of-test-mice 2023-04-26T03:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/9a7a618ea77a4e40/one-week-elderberry-juice-treatment-increases-postprandial-carbohydrate-oxidation 2023-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1bb9f7683171bd87/biogen-receives-fda-approval-for-breakthrough-als-treatment-pivotal-moment-in-als-research 2023-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c99da071c4dbad14/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-for-psma-positive-metastatic-castration-resistant-prostate-cancer 2023-04-24T20:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/aacf277c1c6dc46d/leaked-data-show-cilta-cel-delivers-74-reduction-in-risk-of 2023-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/df673f029e51dae6/psychedelics-may-better-treat-depression-and-anxiety-symptoms-than 2023-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8bb9167d65bcac1e/sleeping-pill-shows-potential-in-reducing-alzheimer-s-proteins 2023-04-20T14:00:47+00:00 weekly 0.7 https://trial.medpath.com/news/21e3686dfe38f13b/fda-grants-fast-track-designation-to-botensilimab-plus-balstilimab-for-non-msi-h-dmmr-metastatic-colorectal-cancer 2023-04-20T13:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/573889ecd1af4dcb/fda-withdraws-authorization-for-original-covid-19-vaccines 2023-04-19T18:11:34+00:00 weekly 0.7 https://trial.medpath.com/news/2b2a980df2c809c1/second-omicron-booster-authorized 2023-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/959d16fe71a1686b/fda-approves-omidubicel-for-blood-cancers-in-need-of-transplant 2023-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/072e10496d310dbc/insilico-medicine-leverages-ai-to-develop-novel-cdk8-inhibitor-for-cancer-treatment 2023-04-13T00:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/d8d5c1be5707f393/naxswabtm-otc-novel-naloxone-nasal-swab-successfully-administered-by-children-and-adults-to-potentially-rescue-someone-from-an-opioid-overdose-in-study 2023-04-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/47026c23a1c1180f/revumenib-shows-breakthrough-results-in-advanced-acute-myeloid-leukemia-trial 2023-04-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/548333cb2ba9c735/almirall-launches-first-dermatology-study-to-assess-patient-wellbeing-as-primary-endpoint-in-psoriasis-treatment 2023-04-12T11:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/b3d1e2ffe4f0d1c3/alebund-pharmaceuticals-secures-nearly-rmb-200-million-in-pre-c-round-financing 2023-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e3a67c2017b485c6/pembrolizumab-plus-lenvatinib-fails-to-meet-primary-endpoints-in-melanoma-and-colorectal-cancer-trials 2023-04-07T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e80ef73ad95b463b/ema-awards-prime-scheme-designation-to-mrna-4157 2023-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6f90e7f78e252ce5/acalabrutinib-avo-triplet-therapy-in-high-risk-cll 2023-04-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/28e99414015844c3/fda-grants-emergency-use-authorization-for-vilobelimab-in-treating-critically-ill-covid-19-patients 2023-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f013f98a6fb84672/nexcella-announces-2023-haematologica-editorial-highlighting-nxc-201-efficacy-in-the-context-of-u-s-food-and-drug-administration-approved-bcma-car-t-cells-nexcella-inc 2023-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c1517d2cbbeb9100/i-mab-provides-business-and-corporate-updates-and 2023-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/54a8d02a29af555d/generic-manufacturers-secure-licenses-for-long-acting-hiv-prevention-drug-cabotegravir 2023-03-30T09:24:25+00:00 weekly 0.7 https://trial.medpath.com/news/c4c951d942d0f775/tracking-the-covid-19-vaccines-the-global-landscape 2023-03-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/92f8c7fcd214934b/atezolizumab-enhances-immunogenicity-in-cervical-cancer-treatment 2023-03-29T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/41f0a7d285e6e887/who-panel-to-review-obesity-drug-liraglutide-for-essential-medicines-list 2023-03-29T14:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/0e74925081e63353/nih-releases-data-showing-more-clinical-trial-sponsors-are-reporting-results-but-most-miss-deadlines 2023-03-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/95a90bd95ce82f5c/fda-issues-guidelines-to-support-applications-for-accelerated-approvals 2023-03-28T19:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/a0996afbeb8efd5c/thermosome-s-the001-receives-regulatory-approval-for-first-in-human-trial-in-soft-tissue-sarcoma 2023-03-28T08:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/1e909febb321e0b3/radiopharm-theranostics-expands-partnership-with-genesiscare-for-phase-i-radiopharmaceutical-trials-in-australia 2023-03-27T15:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/5597ce692ed4128b/kala-pharmaceuticals-provides-safety-update-and-completes-enrollment-for-chase-phase-2b-trial 2023-03-27T12:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/70da79985a519b41/neoadjuvant-pembrolizumab-improves-event-free-survival-in-advanced-melanoma-patients 2023-03-23T14:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/d898a6d5e080110b/olix-pharmaceuticals-receives-approval-for-phase-1-clinical-trial-of-new-hair-loss-treatment 2023-03-23T11:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/72ca596bb9da05e4/asciminib-monotherapy-in-patients-with-cml-cp-without-bcr-abl1-t315i-mutations-treated-with-at-least-two-prior-tkis-4-year-phase-1-safety-and-efficacy-results-leukemia 2023-03-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5ec9252b0bd00780/mhra-introduces-new-measures-to-streamline-clinical-trial-approvals-in-the-uk 2023-03-21T12:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/ff72cfb26cbfeed5/ai-technology-revolutionizes-rare-disease-diagnosis-reducing-detection-time-by-4-4-years 2023-03-20T02:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/ce0e522e580b947c/nubeqatm-darolutamide-approved-for-additional-prostate 2023-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f0656580cbff2a37/toripalimab-combined-with-lenvatinib-and-gemox-is-a 2023-03-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/55a3d05e2bb1d530/bispecific-cd20-cd19-car-t-cell-therapy-shows-promising-results-in-mantle-cell-lymphoma 2023-03-16T15:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/5bff5497600222bd/novo-nordisk-reinstated-to-abpi-after-two-year-suspension-for-code-violations 2023-03-16T03:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/c6a2461d1958a1c6/revumenib-shows-promise-in-phase-1-trial-for-kmt2a-rearranged-and-npm1-mutated-acute-leukemia 2023-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6216b1c81ea2b40d/sapience-therapeutics-receives-ind-clearance-from-fda-to-proceed-with 2023-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/52cb58fa256d0e86/israeli-scientists-develop-world-s-first-mrna-vaccine-against-antibiotic-resistant-bacteria 2023-03-12T07:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/27cc4e4aacdf4863/quanterix-launches-novel-p-tau-205-and-p-tau-212-assays-to-advance-alzheimer-s-research 2023-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/12fbd2c8fd702815/digital-health-measures-transform-patient-care-through-pre-competitive-industry-collaboration 2023-03-10T04:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/8f5cfe6c92f192d3/palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-for-microcystic-lymphatic-malformations 2023-03-09T14:24:54+00:00 weekly 0.7 https://trial.medpath.com/news/0d2c900b3c67c86f/lilly-concludes-solanezumab-development-after-alzheimer-s-study-fails 2023-03-09T12:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/e01351aef8c26531/therapeutic-trials-for-long-covid-19-a-call-to-action 2023-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cda572965d6065e7/invox-pharma-completes-161-million-acquisition-of-f-star-therapeutics-to-strengthen-bispecific-antibody-pipeline 2023-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8a34396f42997f42/randomized-clinical-trial-of-neoadjuvant-therapy-for-escc-shows-promising-results 2023-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ff97910c68c6792d/tailored-axillary-surgery-a-novel-approach-for-clinically-node-positive-breast-cancer 2023-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/71ca21c48c8340d1/moderna-and-msd-s-mrna-cancer-vaccine-shows-44-reduction-in-melanoma-recurrence-risk 2023-03-06T19:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/8d9461279ee184ac/avo-triplet-regimen-continues-to-show-durable-responses-in-high-risk-cll 2023-03-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d6b130870af210df/fda-accepts-sbla-for-traditional-approval-of-leqembi-for-alzheimer-s-disease-treatment 2023-03-05T23:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/36b79a80d91d8831/moderna-to-establish-uk-innovation-and-technology-centre-at-harwell-science-campus-by-2025 2023-03-05T16:15:49+00:00 weekly 0.7 https://trial.medpath.com/news/efe1ccb7cb616ad7/evolution-of-axillary-management-in-breast-cancer-therapy-a-focus-on-de-escalation-and-escalation-strategies 2023-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eca2c03244618dfb/trastuzumab-deruxtecan-gains-regulatory-approvals-in-china-and-europe-for-her2-positive-cancers 2023-03-02T17:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aa0b05cfad5c66ff/impacts-of-fda-approval-and-medicare-restriction 2023-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b1f7ce6ec5f59acd/omission-of-axillary-lymph-node-dissection-in-breast-cancer-patients-with-residual-nodal-disease-after-neoadjuvant-chemotherapy 2023-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7b8ee848d86adaa7/canadian-founded-company-develops-first-ai-designed-covid-19-drug-starts-clinical-trials 2023-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/47b3ea925cd566fc/phase-1b-clinical-trial-results-for-socazolimab-in-es-sclc-treatment 2023-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b436e5f3de7fd9d6/survival-outcomes-in-braf-v600e-mutated-advanced-colorectal-cancer-chemotherapy-alone-vs-chemotherapy-combined-with-bevacizumab 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/913f1a2f6ea765f6/avutometinib-plus-defactinib-generates-responses-in 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/512f19186af33292/ux111-shows-continued-dose-dependent-efficacy-as-an 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6677d3ce940c8d80/blue-lake-biotechnology-s-nasal-covid-19-vaccine-shows-86-efficacy-in-phase-1-trial 2023-02-24T20:26:43+00:00 weekly 0.7 https://trial.medpath.com/news/3c554162510801ae/astrazeneca-completes-1-3-billion-acquisition-of-cincor-pharma-for-hypertension-drug-baxdrostat 2023-02-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c4a2505b564f1fb0/study-to-evaluate-expanded-methadone-access-amid-opioid-crisis 2023-02-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/800fb6cb88450306/is-it-still-worth-pursuing-the-repurposing-of-metformin-as-a-cancer 2023-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/49e3b746ffd42525/promius-pharma-advances-minocycline-hydrochloride-er-development-for-rosacea-treatment 2023-02-22T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b86351e761ea58ca/alteogen-s-subsidiary-completes-phase-iii-enrollment-for-eylea-biosimilar-in-wet-amd 2023-02-22T00:34:10+00:00 weekly 0.7 https://trial.medpath.com/news/3d13608906f2a2ec/doxycycline-for-sti-prevention-highly-effective-minimal-drug 2023-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/76b429e29b5dff79/pharma-industry-braces-for-200b-patent-cliff-as-biologics-face-biosimilar-competition 2023-02-20T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c10f7daaca249574/gsk-s-belantamab-mafodotin-expands-development-portfolio-to-target-diffuse-large-b-cell-lymphoma 2023-02-20T08:21:08+00:00 weekly 0.7 https://trial.medpath.com/news/bc1461523aa461c6/novel-gene-therapies-and-biomarkers-advance-the-fight-against-frontotemporal-dementia 2023-02-20T06:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/92222960edf0399e/pragmatica-lung-trial-pioneers-streamlined-approach-to-cancer-drug-development-in-advanced-nsclc 2023-02-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/df0d9561ca71aefc/bladder-sparing-risk-enabled-therapy-after-initiating 2023-02-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d9ec95e3c798b7ef/fda-approves-lamzede-for-alpha-mannosidosis-treatment 2023-02-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fc9a2d02c8492229/next-generation-adcs-and-serds-transform-breast-cancer-treatment-landscape 2023-02-15T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d97e584ced26e416/acr-initiatives-to-reduce-disparities-in-clinical-trials 2023-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a9956a894352e14d/fda-advisers-to-consider-emergents-ebs-narcan-spray-as-otc-overdose-antidote-bloomberg 2023-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3b3c0e8981e7dc14/lg-chem-completes-571-million-aveo-acquisition-to-accelerate-us-cancer-market-entry 2023-02-14T10:49:01+00:00 weekly 0.7 https://trial.medpath.com/news/6b1cf1ab460a44eb/immunotherapy-significantly-improves-survival-rates-for-operable-bladder-cancer-patients 2023-02-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/47cee236711fdfa8/nci-selects-two-assays-for-vanguard-study-on-multi-cancer-detection-tests 2023-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/68e74626a5bc505b/seastar-medical-receives-fda-approval-to-begin-study 2023-02-09T13:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/01ccc2c430e3311f/people-are-taking-a-20-cent-wonder-drug-to-slow-aging-and-lose-weight-some-doctors-say-it-s-promising 2023-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/019046d6c9b33843/innovative-approaches-in-igan-treatment-the-applause-igan-study 2023-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/137824e1863a9ef9/fda-grants-orphan-drug-designation-to-ezurpimtrostat-for-hcc-treatment 2023-02-08T18:58:44+00:00 weekly 0.7 https://trial.medpath.com/news/b0c2b01025c5f1d6/neogap-receives-approval-for-clinical-trial-cision-news 2023-02-06T06:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/15f65ea0bbbd1bd7/immutep-reaches-enrolment-target-for-insight-003-trial 2023-02-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2120eba253d77ef9/canadian-developed-car-t-cell-therapy-targeting-cd22-heads-to-clinical-trials 2023-02-03T10:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/426d54826dfe250f/major-kinase-inhibitor-summit-to-showcase-next-generation-cancer-therapeutics-advances 2023-02-02T06:45:55+00:00 weekly 0.7 https://trial.medpath.com/news/fec361e3c9aa4c13/real-world-evaluation-of-ocrelizumab-in-multiple-sclerosis-shows-promising-results 2023-02-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/33809f8246424c32/gsks-anemia-drug-gets-fda-nod-only-for-patients-on-dialysis-bloomberg 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4418959a1d30aec4/study-reveals-outcomes-of-panobinostat-in-heavily-pretreated-multiple-myeloma-patients 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cdd272b3e3c10c90/significant-advances-and-collaborations-among-viva-s-portfolio-companies 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/085ae9a097de7bcb/rise-therapeutics-announces-fda-clearance-of-its-ind-application-to 2023-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f625064ece34d8db/palbociclib-plus-endocrine-therapy-in-hormone-receptor 2023-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8427d24a20a5180b/fda-approves-elacestrant-as-first-oral-serd-for-advanced-er-her2-breast-cancer 2023-01-27T21:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/ff51bad258f6ed69/european-medicines-agency-accepts-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease 2023-01-26T23:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/752a0d17361fd1aa/january-2025-fda-brief 2023-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/579f08c64c353c75/alleviant-medical-closes-75m-in-financing 2023-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/861fb007292f68e6/psychedelics-in-medicine-a-renaissance-in-mental-health-treatment 2023-01-25T10:39:46+00:00 weekly 0.7 https://trial.medpath.com/news/a2ebfd53c9daa98b/ai-driven-hcp-engagement-how-life-sciences-companies-are-optimizing-commercial-success-through-data-analytics 2023-01-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/04dc29abf42a36c4/briacell-advances-pivotal-study-for-bria-imt-in-metastatic-breast-cancer-following-positive-fda-feedback 2023-01-24T14:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/79fa9c5ab5845157/artificial-intelligence-enhances-cancer-clinical-trial-enrollment-efficiency 2023-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c5eaef103ba1437e/cd40-directed-sea-cd40-combo-denotes-antitumor 2023-01-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4e718ae5b05e25cd/an-alternative-dosing-strategy-for-ropeginterferon-alfa-2b 2023-01-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4aa9d9505710d48f/ampicillin-proves-effective-against-vre-urinary-tract-infections-despite-resistance-concerns 2023-01-17T08:16:30+00:00 weekly 0.7 https://trial.medpath.com/news/06d34273d2f15cdd/astrazeneca-s-unify-platform-revolutionizes-clinical-trials-with-precision-medicine-and-digital-innovation 2023-01-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5968ba9392c5dd7c/phase-2-3-study-shows-robust-immunogenicity-of-nvx-cov2601-in-vaccine-naive-individuals-with-prior-sars-cov-2-infection 2023-01-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ddc4b013b5515ce1/astrazeneca-discontinues-moxetumomab-pasudotox-for-hairy-cell-leukemia-due-to-low-clinical-uptake 2023-01-13T16:25:58+00:00 weekly 0.7 https://trial.medpath.com/news/f55b2f8438ed100a/fda-approves-first-cgrp-targeting-therapy-for-pediatric-migraine-prevention 2023-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9c2c4b9a1a8238d5/could-this-drug-make-your-dog-live-longer-it-just-cleared-a-major 2023-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f7074a0745d22965/ima-group-expands-clinical-research-network-with-clinical-trials-of-america-acquisition 2023-01-11T12:06:20+00:00 weekly 0.7 https://trial.medpath.com/news/82faf3a601dd3ad6/ensysce-biosciences-highlights-2022-achievements-and-future-plans-in-shareholder-letter 2023-01-11T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a26c9959208f3c5b/adimab-announces-2022-clinical-pipeline-update-with-seven-new-partner-programs 2023-01-11T05:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/174bac4be5d500bd/fda-approval-summary-axicabtagene-ciloleucel-for-second-line-treatment 2023-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2c72e745eae34e4a/fda-grants-fast-track-designation-to-novel-tkk1-therapy-for-er-her2-advanced-breast-cancer 2023-01-10T20:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/4d0c23ba10719a03/phase-ii-study-evaluates-durvalumab-for-bcg-unresponsive-bladder-cancer 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/23c3ff4ffcdcab53/stokes-phase-3-trial-of-stk-001-for-dravet-planned-for-next-year 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8cae93c1fdd9d3ba/folfoxiri-plus-cetuximab-or-bevacizumab-as-first-line-treatment-for-brafv600e-mutant-metastatic-colorectal-cancer 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dfeba415c09caddf/xbb-1-5-likely-resistant-to-evusheld-fda-says 2023-01-09T16:00:27+00:00 weekly 0.7 https://trial.medpath.com/news/e2618cc00fc86106/14-breakthrough-drugs-poised-for-blockbuster-status-by-2027-clarivate-analysis 2023-01-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/79a962507c87e2b8/real-world-weight-loss-effectiveness-of-glp-1-agonists-in-type-2-diabetes-patients 2023-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abdad3b55524970a/syros-pharmaceuticals-inc-nasdaq-syrs-q1-2023-earnings-call-transcript 2023-01-08T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/c9fb877d6251b461/editas-medicine-inc-nasdaq-edit-q4-2022-earnings-call-transcript 2023-01-08T13:01:57+00:00 weekly 0.7 https://trial.medpath.com/news/63b4ffdbc8f2a842/aldeyra-therapeutics-inc-nasdaq-aldx-q4-2022-earnings-call-transcript 2023-01-08T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/e9d3f7fee4ffd142/fda-pulls-eua-granted-to-astrazeneca-s-azn-evusheld 2023-01-08T12:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/f424a917cccdf71c/geron-corporation-nasdaq-gern-q4-2022-earnings-call-transcript 2023-01-08T10:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/740b158e9a95293d/car-t-cell-therapy-reaches-beyond-cancer-penn-bioengineering-blog 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e379eae9265be31d/alzheimers-drug-lecanemab-receives-accelerated-approval-amid-safety-concerns-cnn 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e1c7fc27ad43277c/combomatch-will-test-new-combinations-of-cancer-drugs-nci 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7553dd7a4bad44a3/veeva-experts-predict-data-driven-transformation-in-life-sciences-r-d-for-2023 2023-01-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7dac54c167e3b0a2/cilta-cel-garners-more-positive-data-in-early-and-late-relapsed 2023-01-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/74138378c2629202/bioengineered-probiotic-bacteria-could-replace-injections-for-rheumatoid-arthritis-treatment 2023-01-04T18:55:45+00:00 weekly 0.7 https://trial.medpath.com/news/3f86274d2d6bc918/first-made-in-singapore-antibody-drug-conjugate-adc-approved 2023-01-04T03:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/1fd420515efc0081/european-health-data-space-to-transform-pharmaceutical-research-access-by-2025 2023-01-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3900f1c73e78a942/bdr-pharmaceutical-launches-first-generic-apalutamide-in-india-for-prostate-cancer-treatment 2023-01-03T13:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/6858ddabd1ff5f0b/clinical-and-molecular-effects-of-oral-ccr4-antagonist 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0dbe5f044d5197f5/innovative-clinical-trial-designs-for-glioblastoma-a-new-horizon 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/af7ef66c1fa48176/efficacy-and-safety-of-inebilizumab-in-igg4-related-disease-pubmed 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/68357d8a760945d2/clover-biopharmaceuticals-advances-rsv-vaccine-scb-1019-with-u-s-ind-clearance-for-revaccination-study 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0f39307a9617ccb5/gene-therapy-for-hemophilia-a-new-horizon-in-treatment 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4db23cb93af3a4a2/a-good-use-of-time-providing-evidence-for-how-effort-is-invested-in 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/15cc43120e53075a/emergency-use-authorization-eua-revoked-for 2022-12-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/71a6bbe4bf541428/lecanemab-in-patients-with-early-alzheimer-s-disease 2022-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b87838c3ec0b19d5/boehringer-ingelheim-and-click-therapeutics-expand-digital-therapeutics-alliance-for-schizophrenia-in-460m-deal 2022-12-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/267ea71fc229ace9/eagle-pharmaceuticals-receives-fda-approval-for-additional-indication-for-pemfexy-r-in-combination-with-pembrolizumab-and-platinum-chemotherapy 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/39a7f0e49af02243/vergent-bioscience-completes-enrollment-in-phase-2-visualize-trial 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cdecb98a94a762a5/fda-approves-nadofaragene-firadenovec-for-high-risk-non-muscle-invasive-bladder-cancer 2022-12-16T20:56:59+00:00 weekly 0.7 https://trial.medpath.com/news/efa7d0adecd44a3d/renovorx-announces-acceptance-of-four-clinical-data-abstracts-at-the-2023-asco-gastrointestinal-cancers-symposium 2022-12-15T12:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/07dd6bd186c10c48/iterum-therapeutics-announces-issuance-of-allowance-for-a-u-s-patent-covering-oral-sulopenem 2022-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a8a47035b89a1fbb/nhs-innovation-commission-charts-path-for-uk-healthcare-transformation-and-life-sciences-growth 2022-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3cb598d39208a3a4/challenges-and-advances-in-alzheimer-s-and-parkinson-s-disease-research 2022-12-13T16:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/0c8bfffa5c74450e/rsv-emerges-as-hidden-threat-to-elderly-population-causing-8000-annual-deaths-in-uk 2022-12-13T09:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/c8c6528498b65209/biogen-advances-digital-health-innovation-in-neurology-through-four-pillar-strategy 2022-12-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b62c0471e0222004/elranatamab-achieves-61-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2022-12-10T23:00:37+00:00 weekly 0.7 https://trial.medpath.com/news/08ba7d4cecd4fd67/psilocybin-assisted-therapy-mediates-psycho-social 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2f01f874d514f2bf/agios-presents-updated-pyrukynd-r-mitapivat-data-highlighting-long 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/db88761ea31bb0e2/intrabio-completes-over-enrollment-for-pivotal-niemann-pick-disease-type-c-trial-data-expected-q2-2023 2022-12-08T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/62ef6be90061121b/novartis-investigational-iptacopan-provides-clinically-meaningful-increases-in-hemoglobin-levels-in-complement-inhibitor-naive-patients-with-pnh 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0bc0c17e9bea71b6/car-t-cell-therapy-shows-promise-despite-significant-safety-challenges-in-clinical-trials 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cfb39ab44b36f5e8/uk-life-sciences-council-lacks-transparency-despite-critical-industry-role 2022-12-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/148252f8d091f38a/yonalink-secures-6m-investment-to-transform-clinical-trial-data-management-with-real-time-streaming-technology 2022-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f6bcfbaa4f7ee76d/heparegenix-reports-positive-topline-results-of-its-phase-1-clinical 2022-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1ed409b7e6914ef9/novel-hiv-vaccine-shows-97-antibody-response-rate-in-phase-1-trial 2022-12-01T19:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/5d91d7cc0a912214/ai-powered-analytics-transform-clinical-trial-design-and-enrollment-strategy 2022-12-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f0cea76b3517c384/fda-approves-olutasidenib-for-acute-myeloid-leukemia-subtype 2022-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e1358ab20f0aed7a/industry-leaders-push-for-patient-centric-clinical-trials-through-technology-and-community-engagement 2022-11-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1e1cf5a7c758ee94/alzheimer-s-drug-lecanemab-hailed-as-momentous 2022-11-30T01:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/003599ca6dc976b8/experimental-drug-appears-to-slow-progression-of-alzheimers-disease-in-clinical-trial-but-raises-safety-concerns-cnn 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1df0627c6c88b119/car-t-cell-therapy-reaches-beyond-cancer-penn-today 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/da2e195f83776574/roche-withdraws-tecentriq-from-bladder-cancer-market-following-failed-confirmatory-trial 2022-11-29T16:26:54+00:00 weekly 0.7 https://trial.medpath.com/news/eb0c8cca91ea1c4f/mhra-and-nhs-england-fast-track-novel-prostate-cancer-treatment-darolutamide-combination-therapy 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9a09cde8b3d956b0/automation-emerges-as-key-solution-to-pharmaceutical-supply-chain-vulnerabilities 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9f118125f59be9cb/new-drug-development-pipeline-shows-promise-for-als-treatment-with-53-candidates-under-investigation 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cc18aa8316308ed9/rare-disease-drug-development-faces-critical-forecasting-challenges-with-only-5-having-approved-treatments 2022-11-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e98f5f0498db50c2/margetuximab-does-not-surpass-trastuzumab-in-terms-of 2022-11-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/46a1074f1933dbe6/fda-approves-teplizumab-first-disease-modifying-drug-for-type-1-diabetes-prevention 2022-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b2a82f530aa9ad85/fierce-biotech-fda-wants-confirmatory-trials-to-be-underway-before 2022-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d9819315207b0e3/raesedo-inc-awarded-3-4m-sttr-grant-to-develop-new-asthma-therapies 2022-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ec3c29ddeff6f96d/characteristics-of-measurable-residual-disease-assessment-in-myeloma-a 2022-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e735e39d9a816c95/healthcare-investment-landscape-shows-signs-of-stabilization-after-2021-surge-industry-leaders-report-at-lsx-showcase 2022-11-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d380982f93b28a66/roche-s-gantenerumab-fails-to-meet-primary-endpoints-in-phase-3-alzheimer-s-trials 2022-11-14T08:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/80e084070b8de8a8/viridian-announces-positive-data-from-ongoing-phase-1-2-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted 2022-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d6acb769502fbdb6/xeltis-starts-pivotal-clinical-trial-with-first-ever-restorative 2022-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d584cacc7db5ac1f/paxlovid-may-reduce-risk-of-long-covid-study-suggests 2022-11-09T21:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/c441730a0e66c6e7/aquatic-vaccines-current-status-and-future-development-prospects-in-global-aquaculture 2022-11-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5e7d69b6668b7086/fda-approves-regeneron-s-libtayo-combination-for-non-small-cell-lung-cancer-treatment 2022-11-09T12:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/876177db5edf7aa4/real-world-first-line-treatment-patterns-and-outcomes-for-brafv600e-mutant-metastatic-colorectal-cancer-in-europe 2022-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ddea74e238041f7e/impact-of-mrd-status-and-number-of-remissions-on-hsct-outcomes-aml-hub 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/66290bff575c869f/baxdrostat-shows-dramatic-blood-pressure-reduction-in-treatment-resistant-hypertension-trial 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/29423048b9fae257/top-biotech-stocks-for-q2-2023 2022-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4eb32053828212e8/treasure-data-releases-whitepaper-on-maximizing-data-utilization-in-pharmaceutical-industry 2022-11-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a0150d5a36609ccf/moderna-sues-pfizer-and-biontech-over-mrna-covid-19-vaccine-patent-infringement 2022-11-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f11e9d06f6923630/sirona-completes-enrollment-a-leap-in-the-dcb-treatment-of 2022-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c00282ebcdbe585c/stem-cell-strategies-show-promise-for-rebuilding-brain-tissue-in-neurodegenerative-diseases 2022-11-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fd72473b6e5fcb3b/topical-tranexamic-acid-reduces-blood-loss-in-knee-arthroplasty-study-finds 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c7b3191cd34d0471/small-business-americus-times-recorder-americus-times-recorder 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f36c528e94c27376/eli-lilly-invests-92-5m-in-purdue-university-to-advance-pharmaceutical-manufacturing-and-research 2022-10-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/710a716ad707e015/invitae-study-shows-therapy-informed-by-genetic-testing-reduces-seizures-in-some-patients-with-epilepsy 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/91542434d14769b3/monoclonal-antibody-prevents-malaria-infection-in-african-adults 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dc2ec23ff65aa04d/prospective-open-label-single-arm-single-center-follow-up-study-of 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adea3c5373043257/medical-device-advances-in-the-treatment-of-glioblastoma 2022-10-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9696aed038b90f8d/genmab-and-abbvie-submit-regulatory-applications-for-epcoritamab-bispecific-antibody-in-relapsed-refractory-b-cell-lymphomas 2022-10-28T12:46:06+00:00 weekly 0.7 https://trial.medpath.com/news/32222e074bf9711d/fda-approves-astrazeneca-s-dual-immunotherapy-combination-for-unresectable-liver-cancer 2022-10-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a297944afb025e6d/ivermectin-a-drug-once-touted-as-a-covid-treatment-by-conservatives-doesn-t-improve-recovery-much-clinical-trial-finds 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5360d308a7289988/sequana-medical-announces-positive-top-line-results-from 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1456a519cf5c2952/evotec-receives-2-5m-gates-foundation-grant-for-ipsc-based-teratogenicity-platform 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/529824f76cb04758/f2g-s-olorofim-shows-44-response-rate-in-phase-2b-trial-for-invasive-fungal-infections 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5e2195d82f7a8e1e/intraventricular-b7-h3-car-t-cells-for-diffuse-intrinsic 2022-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d670a1c9f352cc0f/mereo-biopharma-announces-updated-operating-plan-to-maximize-shareholder-value 2022-10-18T11:06:14+00:00 weekly 0.7 https://trial.medpath.com/news/588b65b0d04b20f6/nanopharmaceutics-completes-enrollment-in-phase-2-neuroendocrine-tumor-study-combining-triapine-with-lutetium-lu-177-dotatate 2022-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2fa759aa4e2de74c/eli-lilly-acquires-akouos-for-610m-to-expand-gene-therapy-portfolio-in-hearing-loss-treatment 2022-10-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/24699ccc56b7b16c/attralus-enrolls-first-subject-in-phase-1-clinical-trial-for-at-02-a-pan-amyloid-removal-therapeutic 2022-10-17T11:06:06+00:00 weekly 0.7 https://trial.medpath.com/news/70500e7eb03e5651/fda-grants-rmat-and-fast-track-designations-to-caribou-s-allogeneic-car-t-therapy-cb-010-for-b-cell-lymphoma 2022-10-14T18:00:39+00:00 weekly 0.7 https://trial.medpath.com/news/b9f6696f1b939ef9/neoadjuvant-immunotherapy-shows-promise-in-melanoma-treatment-two-studies-demonstrate-improved-outcomes-with-pre-surgery-approach 2022-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4afddd978e2e38c6/significant-improvement-in-overall-survival-with-adjuvant-olaparib-in-high-risk-early-breast-cancer-patients-with-brca1-2-mutations 2022-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/85bb2194f0816ef0/insulin-glargine-and-liraglutide-show-superior-performance-in-large-type-2-diabetes-comparative-trial 2022-10-07T16:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/f8f990af32267db2/xeltis-presents-promising-first-in-human-data-on-restorative 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4d185eff2c774ac2/reproxalap-for-dry-eye-disease-aldeyra-therapeutics-inc 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cb43edcdd211f499/uab-research-finds-obesity-drug-can-reduce-the-risk-of-type-2-diabetes 2022-10-06T16:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/f5ed6706fbb570c9/aerorx-and-hcmed-partner-to-develop-first-nebulized-laba-lama-combination-for-copd-treatment 2022-10-02T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e0c3889177b537df/a-prospective-single-centre-open-label-single-arm-pilot-study-to 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1a0fefa819e6ce1e/glp-1-receptor-agonists-show-significant-weight-loss-benefits-in-overweight-and-obese-patients 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8790b94fef53b567/initial-safety-run-in-results-of-the-phase-3-lotis-5-trial-for-r-r-dlbcl-treatment 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ba2890fa58987151/mpn-545-surpass-et-ropeginterferon-alfa-2b-p1101-vs-anagrelide-as 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a6ca64114b318631/fda-watchdog-report-reveals-one-third-of-accelerated-approval-drugs-lack-confirmatory-trial-data 2022-09-30T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/ff8d7ded6265763e/alzheimer-s-slowing-drug-labelled-historic 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e8430e89159f9bb2/photocure-and-karl-storz-launch-advanced-blue-light-cystoscopy-system-in-us-market 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/109c1ecee74282c7/population-pharmacokinetic-pharmacodynamic-analyses 2022-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/99f0503903de9b2e/lipocine-pivots-to-cns-disorders-with-oral-neuroactive-steroid-pipeline 2022-09-26T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c8a31f2aee2dbe1b/cytokine-profile-at-diagnosis-affecting-trough 2022-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/62a0792231b9c7ee/genetically-modified-herpes-virus-shows-promise-against-advanced-cancers-in-early-trial 2022-09-22T23:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/20ca953ff2a38c72/real-world-study-shows-axicabtagene-ciloleucel-outperforms-tisagenlecleucel-in-relapsed-refractory-dlbcl 2022-09-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/12c14063d2cdc8f5/experts-call-for-reform-in-experimental-treatment-access-balancing-patient-rights-with-sustainable-development 2022-09-17T04:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/d0ea6ba6c2d2afc2/fda-grants-breakthrough-therapy-designation-for-affinity-enhanced-t-cell-therapy-in-synovial-sarcoma 2022-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a971ce3ef6db682a/adeno-associated-virus-gene-therapy-for-hemophilia-a-new-therapeutic-paradigm 2022-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d407920114d9cd17/fda-grants-fast-track-designation-to-mersana-therapeutics-xmt-1660-for-triple-negative-breast-cancer-treatment 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/158c20220929ac1d/synergia-medical-secures-eur9-million-in-series-b-funding-for-epilepsy-treatment-innovation 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7179dfc7fd426e7c/low-dose-interleukin-2-shows-promise-in-slowing-motor-neurone-disease-progression-in-landmark-mirocals-trial 2022-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4b0444e6eebe5800/tecvayli-shows-promising-outcomes-in-treating-advanced-multiple-myeloma 2022-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6faf514d9b1661c6/entrepreneurial-accelerator-program-eap-portfolio-company-receives-400000-research-grant-from-the-national-cancer-institute-to-study-a-repurposed-drug-in-treatment-of-glioblastoma 2022-09-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c4b479e110bd123c/ashvattha-therapeutics-advances-in-medical-research-and-clinical-trials 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f79638007b7cc517/fda-grants-priority-review-for-trodelvy-in-hr-her2-metastatic-breast-cancer-following-positive-survival-data 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a7db0a8107ffb303/continuous-circadian-intracerebroventricular 2022-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6d45c229e46d2804/fluoguide-receives-approval-for-phase-ii-trial-in-head-and-neck-cancer 2022-09-06T11:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/605365510edb280a/neoadjuvant-immunochemotherapy-shows-promise-for-early-stage-small-cell-lung-cancer-surgery 2022-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8167cb05d46530e5/clinical-platform-trials-for-coronavirus-covid-19-treatments-gov-uk 2022-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/34be315a3746ea51/standardizing-eligibility-criteria-a-new-approach-to 2022-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0618e6fe81060df4/brodalumab-improves-health-related-quality-of-life-in-psoriasis-patients-itching-remains-a-challenge 2022-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/78eb9d8aaf77fdd9/novartis-scemblix-r-with-novel-mechanism-of-action-approved-by 2022-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/376fe8310819adc6/psychedelic-clinical-trials-enter-new-era-key-protocol-design-and-safety-considerations-emerge 2022-08-28T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/086ab11748d34496/impact-of-teclistamab-and-talquetamab-on-soluble-bcma-levels-in-multiple-myeloma-treatment 2022-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9715101c5ba58150/bayer-submits-application-in-china-for-additional-indication 2022-08-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ca6b04514b0992a0/k36-therapeutics-receives-fda-clearance-for-first-in-class-multiple-myeloma-drug-ktx-1001 2022-08-23T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/47c55ed309134295/next-generation-rna-technologies-promise-longer-lasting-therapeutics-beyond-mrna 2022-08-22T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f648e621887ff68f/eye-on-pharma-celltrion-aims-for-adalimumab-interchangeability-phase 2022-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ec3ef3e24d14f360/cambridge-researchers-successfully-convert-kidney-blood-types-to-universal-o-potentially-expanding-transplant-access 2022-08-15T07:02:31+00:00 weekly 0.7 https://trial.medpath.com/news/cfda3ed2b0fe15fd/fda-approves-decitabine-and-cedazuridine-tablets-for-myelodysplastic-syndromes 2022-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/be5b03c953ac80bd/positive-results-from-b-clear-phase-iib-trial-for-bepirovirsen-in-chronic-hepatitis-b-treatment 2022-08-11T14:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/5cef38dd5a32daef/a-lyme-disease-vaccine-is-in-its-final-clinical-trial-npr 2022-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/90dccb6f8b5340cd/as-billionaires-race-to-fund-anti-aging-projects-a-much-discussed-trial-goes-overlooked 2022-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/865054cc61fc1e96/tagrisso-plus-savolitinib-shows-promising-49-response-rate-in-egfr-mutated-lung-cancer-with-met-resistance 2022-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f988b62beb22d70d/nek7-emerges-as-promising-inflammasome-target-despite-novartis-study-raising-questions-about-universal-requirement 2022-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d0d7f55ba643e8c8/bellaseno-initiates-clinical-trials-for-resorbable-breast-and-chest-implants 2022-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4048b99e4de646ca/efficacy-and-safety-of-anlotinib-in-extensive-stage-small-cell-lung-cancer 2022-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d65e7db40b82c084/fda-s-accelerated-approval-program-shows-strong-performance-despite-recent-criticisms-analysis-reveals 2022-07-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6efc36bf6c5e4275/our-dna-could-affect-the-potency-of-psychedelics-in-the-brain 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c6812933b60a9337/doxypep-using-antibiotics-to-prevent-stis 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a72ec6a812a79db8/oral-carbapenems-promise-peril-and-pushbacks 2022-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6a7870fcfac0df57/with-merck-known-as-msd-outside 2022-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/05750285f600d35a/senate-finance-committee-revises-medicare-drug-negotiation-policy-removing-automatic-inclusion-of-insulins 2022-07-25T17:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/db01a6ca6df8f783/sling-therapeutics-initiates-enrollment-in-phase-2b-lids-clinical-trial-for-thyroid-eye-disease 2022-07-25T12:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/ccfcca1b3578e055/test-reliability-and-compliance-to-a-twelve-month-visual 2022-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1718f655e2168296/spectral-medical-provides-update-on-tigris-clinical-trial-biospace 2022-07-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e51bf7c1aa53ac0e/cardiofocus-advances-in-pulsed-field-ablation-technology-for-atrial-fibrillation-treatment 2022-07-19T10:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/39c8da086afdf2df/nhs-england-approves-two-life-extending-breast-cancer-drugs-after-initial-rejection 2022-07-14T05:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/989ed0ed208c3513/fda-authorizes-novavax-s-protein-based-covid-19-vaccine-for-us-adults 2022-07-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d0de824f330a577c/fda-grants-orphan-drug-and-fast-track-designations-to-cv-01-for-recurrent-glioblastoma-treatment 2022-07-13T15:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/4b825383d92180ee/a-phase-ii-study-of-retifanlimab-incmga00012-in-patients 2022-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/538bb1a7b2ea7bf8/sequana-medical-announces-unconditional-ide-approval-from-u-s-fda-to 2022-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e096d971ab726efa/sunvozertinib-shows-promising-37-5-response-rate-in-phase-i-trial-for-egfr-exon-20-insertion-nsclc 2022-07-06T13:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/d40a5c89614acf68/the-fda-accepts-bla-and-grants-priority-review-for-lecanemab-for 2022-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d86c87de539f75c1/fda-approves-belumosudil-for-chronic-graft-versus-host-disease-treatment 2022-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/44f90c5dc98cef5f/margetuximab-versus-trastuzumab-in-patients-with 2022-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2093102cf3bde1aa/first-patient-dosed-in-groundbreaking-stem-cell-therapy-trial-for-drug-resistant-epilepsy-shows-dramatic-seizure-reduction 2022-06-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/05ab6b2e9ed8e68d/comprehensive-vaers-analysis-confirms-safety-profile-of-pneumococcal-vaccines-across-multiple-formulations 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ba0f878d4ba60ed0/novartis-nvs-gets-positive-chmp-opinion-for-scemblix-in-cml 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6c61785cfa1515d4/ruxolitinib-plus-steroids-shows-superior-early-response-in-first-line-acute-gvhd-treatment 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/28afa12b48e4a1c3/car-t-therapy-demonstrates-superior-efficacy-over-bispecific-antibodies-in-relapsed-refractory-follicular-lymphoma 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4dfba17cfc21c47d/novel-antibody-drug-conjugate-l-dos47-shows-safety-profile-in-phase-i-ii-nsclc-trial 2022-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d95ca7d03314382d/hong-kong-study-reveals-comparable-safety-profiles-between-coronavac-and-bnt162b2-covid-19-vaccines 2022-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a9d60cb02b55c808/novartis-receives-positive-chmp-opinion-for-scemblix-r-a-novel 2022-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2ff01baa7af1cfe/penn-researchers-earn-nearly-1-billion-from-mrna-covid-vaccine-technology-royalties 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/76fb88de652112ea/novartis-gets-accelerated-fda-approval-for-dabrafenib-trametinib 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e1f6b483867a0984/fda-gives-approval-for-novartis-tafinlar-mekinist-broadens-braf-mek-cancer-combo-use 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8d061b72c23727d8/study-on-brentuximab-vedotin-combination-therapy-for-relapsed-refractory-dlbcl-shows-promising-results 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/95871b167eb71a60/real-world-outcomes-with-fedratinib-in-myelofibrosis-patients-post-ruxolitinib-discontinuation 2022-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7799fbefe50e5101/advances-in-the-clinical-development-of-oncolytic-viruses 2022-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/660a40346f1373bd/valbiotis-announces-major-success-in-phase-ii-heart-clinical-study-for-totum-070 2022-06-13T16:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/343d22e6698ce0b9/sling-therapeutics-launches-with-35m-series-a-financing-to-develop-oral-small-molecule-for-thyroid-eye-disease 2022-06-13T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/23d0e8a830ca4856/lead-pharma-and-oxeltis-secure-eur800k-grant-to-develop-first-in-class-dlbcl-therapy 2022-06-09T10:50:10+00:00 weekly 0.7 https://trial.medpath.com/news/e791534777bf33de/bayer-s-bluerock-therapeutics-expands-to-europe-with-new-berlin-site 2022-06-09T01:22:41+00:00 weekly 0.7 https://trial.medpath.com/news/f35960365b865d64/liquid-biopsy-technology-fda-s-latest-guidance-supports-cooley 2022-06-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/77e879976ec4a2fc/dbv-technologies-announces-positive-topline-results-from-phase-3-epitope-trial-of-viaskin-peanut-in-peanut-allergic-toddlers 2022-06-07T20:36:06+00:00 weekly 0.7 https://trial.medpath.com/news/03959506e2bdb594/dostarlimab-achieves-100-complete-response-rate-in-rectal-cancer-trial-with-mismatch-repair-deficiency 2022-06-06T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3a76da26e2e8e06c/eli-lilly-s-tirzepatide-shows-unprecedented-22-5-weight-loss-in-phase-3-obesity-trial 2022-06-06T10:03:51+00:00 weekly 0.7 https://trial.medpath.com/news/934e44b90402e55a/fda-approves-fifth-neulasta-biosimilar 2022-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c8307632ff70d904/eagle-pharmaceuticals-submits-nda-for-landiolol-ultra-short-acting-beta-blocker-for-critical-care-tachycardia 2022-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d018eaf57d1c30da/risankizumab-as-induction-therapy-for-crohn-s-disease-results 2022-05-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/81a95c7d61715a76/i-mab-reports-latest-phase-2-clinical-data-of-its-differentiated-cd73 2022-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/099031d6da92dca5/abbvie-s-risankizumab-and-upadacitinib-show-promise-in-phase-3-ibd-trials-published-in-the-lancet 2022-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/caee36e76bc16930/phase-ii-study-shows-atacicept-s-potential-in-treating-iga-nephropathy 2022-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/279179d6218c6974/fda-approves-ivosidenib-plus-azacitidine-for-certain-patients-with-acute-myeloid-leukemia 2022-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/92c3c83d668ecd44/comparative-evaluation-of-laxaplus-barij-r-and-polyethylene-glycol-in-pediatric-functional-constipation 2022-05-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3f9f56a1ef6a171a/efficacy-and-safety-of-elian-granules-in-treating-chronic-atrophic-gastritis 2022-05-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/91a43d268e9bc82c/the-fda-approves-epsolay-cream-for-rosacea-treatment-spa-clinic 2022-05-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ec96fecbc43636d4/real-world-evidence-of-axicabtagene-ciloleucel-for-the-treatment-of 2022-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/77685c741e9441c0/teclistamab-daratumumab-combination-shows-promising-results-in-heavily-pretreated-multiple-myeloma-patients 2022-05-20T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1261f90272d7cb78/moderna-faces-patent-infringement-lawsuit-over-lipid-nanoparticle-technology-in-covid-19-vaccine 2022-05-19T09:35:35+00:00 weekly 0.7 https://trial.medpath.com/news/09d6b206393b7b60/clinical-trial-nct04857372-uchicago-medicine 2022-05-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d36397116dca4293/a-pathological-complete-response-after-nivolumab-plus 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/98c25b720507608a/ultragenyx-acquires-global-rights-to-aav-gene-therapy 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/56a92399d01c4e2f/sorrento-s-license-partner-lee-s-pharm-announces-full-enrollment-in-phase-iii-trial-of-socazolimab-for-es-sclc 2022-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ac7832eca6d6b587/cullinan-oncology-and-taiho-pharmaceutical-forge-275m-strategic-collaboration-for-egfr-inhibitor-cln-081-tas6417 2022-05-12T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/013511f822a9e1c5/single-cell-study-reveals-jun-as-key-regulator-in-cardiovascular-aging 2022-05-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e3298b3303be3fb1/delaware-jury-awards-bgi-333-8-million-in-dna-sequencing-patent-victory-against-illumina 2022-05-06T19:45:48+00:00 weekly 0.7 https://trial.medpath.com/news/5ada933259555c1c/car-t-cell-therapy-advances-from-manufacturing-innovations-to-solid-tumor-breakthroughs 2022-05-05T17:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/625a3a4b158dedfb/pharmather-secures-u-s-patent-for-advanced-ketamine-production-technology 2022-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dc0cd7f2c4246fb0/4sc-resminostat-and-resmain-study-update-4sc-ag 2022-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/05aab894ca3c5661/seastar-medical-receives-fda-breakthrough-device-designation-for-novel-therapy 2022-05-03T08:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/aa98c24836b0e573/fda-grants-breakthrough-therapy-designation-to-trastuzumab-deruxtecan-for-her2-low-metastatic-breast-cancer 2022-05-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c616055a098b6aea/six-monthly-injection-shows-promise-as-alternative-to-daily-blood-pressure-medication-in-global-trial 2022-04-27T13:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/ec6c7cab0d2684e7/dual-targeting-car-t-therapies-show-promise-in-overcoming-b-cell-cancer-treatment-resistance 2022-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8e06dc9916db8d03/study-shows-promising-results-for-bioresorbable-polymer-scaffold-in-spinal-cord-injury-patients 2022-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/68193914d262eb0c/current-clinical-trials-in-traumatic-brain-injury 2022-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6a0cce05b1660221/diet-and-gut-microbiota-shape-development-of-regulatory-t-cells-study-finds 2022-04-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ecf776a88bda4bb7/canada-abandons-controversial-drug-pricing-reforms-following-court-ruling 2022-04-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/07f322dbd7aeef51/novel-therapies-transform-multiple-myeloma-treatment-landscape-car-t-bispecifics-lead-innovation-wave 2022-04-15T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4db3358096bdf276/u-s-fda-extends-review-of-biologics-license-application 2022-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6f42e285e9846369/fda-approves-sotorasib-for-kras-g12c-mutated-metastatic-nsclc 2022-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/231716a8a6ac2e9e/new-research-defines-positive-mental-health-literacy-as-key-to-psychological-wellbeing 2022-04-13T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/50c4faeab8de63ee/bo-112-plus-pembrolizumab-shows-promise-in-pd-1-resistant-advanced-melanoma 2022-04-12T20:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/dedbec0dbcb8f3ab/aeglea-biotherapeutics-submits-bla-for-pegzilarginase-as-first-potential-treatment-for-arginase-1-deficiency 2022-04-12T10:52:00+00:00 weekly 0.7 https://trial.medpath.com/news/76af63164e1721ed/dr-tagawa-on-the-investigation-of-225ac-j591-and-177lu 2022-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e9aba9c3b45a7296/study-finds-drug-treatment-effective-for-crohn-s-disease-strictures 2022-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9972c371c299a01f/acadia-to-seek-first-ever-fda-approval-in-rett-syndrome 2022-04-07T10:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/a178b44093e3913f/direct-biologics-reveals-successful-outcomes-from-exit-covid-19-phase-ii-clinical-trial 2022-04-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6d4be5bea345737b/first-patient-dosed-in-phase-2b-trial-of-rt234-a-novel-inhaled-therapy-for-pulmonary-arterial-hypertension 2022-04-05T12:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/b14020af7fb4c145/pacritinib-paves-a-unique-lane-of-treatment-for-select 2022-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/20d70091d8a55242/sequana-medical-completes-alfapump-implantations-in-poseidon-study 2022-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bee8f587a6861fd2/china-clears-cansinobio-covid-19-vaccine-for-clinical-trials-national-globalnews-ca 2022-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d3bda31fcdeec9f4/junshi-biosciences-announces-fda-approval-of-investigational-new-drug-application-for-anti-cd112r-monoclonal-antibody-for-treatment-of-advanced-solid-tumors-financial-post 2022-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fea37241ed015c54/clarity-pharmaceuticals-launches-cobra-trial-testing-novel-cu-64-sar-bispsma-imaging-agent-for-biochemically-recurrent-prostate-cancer 2022-04-01T16:17:02+00:00 weekly 0.7 https://trial.medpath.com/news/485abef19cbc364a/phase-1-dose-expansion-trial-of-brentuximab-vedotin-and-lenalidomide-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2022-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/72fc81cf172882e0/aion-labs-launches-ai-initiative-to-revolutionize-antibody-drug-development 2022-03-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6af780cff0f039de/hhs-terminates-500-million-in-federal-mrna-vaccine-research-funding-under-kennedy-leadership 2022-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9c154e7b7bd16218/pipeline-watch-13-approvals-and-five-topline-phase-iii-readouts 2022-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c33ef894b2d40fd2/us-food-and-drug-administration-revises-emergency-use 2022-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ac9589cc1eabfabb/biopharma-companies-see-massive-potential-in-connected-health-despite-low-adoption-rates 2022-03-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d226f113d58b9a5f/vr-and-ar-technologies-transform-pharmaceutical-manufacturing-training-promising-50-faster-onboarding 2022-03-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fd8ba9742029f900/orphan-drug-market-set-to-reach-350-billion-by-2028-as-rare-disease-treatments-expand 2022-03-18T14:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/e5da9eff771fcc09/feasibility-and-acceptability-of-a-mobile-application-to-monitor-opioid-use-post-cesarean-section 2022-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d802559c00ac851/advancements-in-immune-checkpoint-inhibitor-based-systemic-therapy-for-hepatocellular-carcinoma 2022-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c49efccdd38a46a8/eskayef-pharmaceuticals-becomes-third-bangladeshi-company-to-receive-us-fda-approval-for-manufacturing-facility 2022-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a3d7a78a0d7d8c42/pfizer-begins-phase-2-and-3-trial-of-covid-19-antiviral-paxlovid-in-children-ages-6-to-17-cnn 2022-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f26c2937ad0faab6/fda-approves-carvykti-car-t-cell-therapy-for-multiple 2022-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1d408a5285504e07/promising-brain-cancer-vaccine-survaxm-enters-phase-2b-trial-for-newly-diagnosed-glioblastoma 2022-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/afbf5a4e8b693a3a/comparative-efficacy-of-treatment-regimens-for-transplant-ineligible-patients-with-newly-diagnosed-multiple-myeloma 2022-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ce900cfcb07df485/i-mab-receives-fda-orphan-drug-designation-for-its-novel-claudin-18-2-x 2022-03-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ce1684c8b4d67dd6/exploring-the-role-of-immunotherapy-after-progression-in-renal-cell-carcinoma 2022-03-02T14:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/2c63bf216e2feffd/psychedelic-medicine-gains-mainstream-acceptance-as-mental-health-crisis-drives-research-innovation 2022-03-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/49143bd0b3bd8b92/clinical-trials-missing-in-regulatory-documents-for-extended-release-methylphenidate-applications 2022-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4d16ee6d8ba0060f/combination-therapy-shows-promise-for-advanced-hepatocellular-carcinoma 2022-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/88fd4ddfc733a631/primary-care-sites-emerge-as-vital-hub-for-clinical-research-innovation-experts-highlight 2022-02-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2af2252a0df0c218/first-wholly-ai-developed-drug-enters-phase-1-trials 2022-02-25T04:45:46+00:00 weekly 0.7 https://trial.medpath.com/news/ff7580db4c4342ff/new-sanofi-and-gsk-vaccine-demonstrates-strong-protection-against-severe-covid-19-in-clinical-trials-cnn 2022-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8477be5155612c91/real-world-evidence-shows-immune-checkpoint-inhibitors-benefit-nsclc-patients-with-poor-performance-status 2022-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eaaaf1e4e7675db8/agios-announces-fda-approval-of-pyrukynd-r-mitapivat-as-globenewswire 2022-02-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ab2258ab47d5f3d9/clinical-trial-highlights-positive-effects-of-medical-cannabis-on-ptsd 2022-02-16T15:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/8c982fe513ac4064/poly-adp-ribose-polymerase-parp-inhibitors-for-the 2022-02-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7fb118d20be386b3/pipeline-rise-therapeutics 2022-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e4b545e30e68f3b7/challenges-and-recommendations-in-glioblastoma-clinical-trials 2022-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/361f9439521154f1/fda-plan-to-fast-track-pfizer-vaccine-for-kids-under-5-fails-to-deliver-leaving-parents-waiting-until-april 2022-02-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/99549c944bb7cc05/chromadex-strengthens-patent-portfolio-with-two-new-continuation-patents-for-nicotinamide-riboside-manufacturing 2022-02-09T11:36:07+00:00 weekly 0.7 https://trial.medpath.com/news/c293e89a32861414/combination-therapy-for-pancreatic-cancer-anti-pd-l-1-based-strategy 2022-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b9d6f356ce5024e/cytokinetics-announces-fda-acceptance-of-new-drug-globenewswire 2022-02-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c520742ea15025ac/moderna-s-covid-19-vaccine-spikevax-receives-full-fda-approval-marking-company-s-first-licensed-product 2022-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dc8b937fe3b555e5/calliditas-reports-positive-phase-iii-results-for-nefecon-plans-full-fda-approval-filing-in-2023 2022-01-28T07:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/9088c766a9bc6a2c/early-research-suggests-cancer-drug-could-help-flush-hiv-from-its-hiding-spots 2022-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5221da2cab10f814/transitioning-ongoing-studies-to-the-eu-clinical-trial-regulation 2022-01-25T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/c5c83638f0e36859/can-cbd-treat-covid-19-clinical-trials-still-needed-researchers-warn-national-globalnews-ca 2022-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fcf3e6207db93c67/johnson-johnson-medtech-receives-ce-mark-approval-for-advanced-dual-energy-thermocool-smarttouch-sf-catheter 2022-01-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2d557a16072d2de9/adimab-announces-2021-clinical-pipeline-update-with-12-new-partner-programs 2022-01-19T05:13:42+00:00 weekly 0.7 https://trial.medpath.com/news/b132526f94e48019/prophylactic-tranexamic-acid-in-hematologic-malignancy-patients-a-randomized-clinical-trial 2022-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6b82bd436ac7fd3e/edap-announces-positive-pre-clinical-results-for-hifu-ablation-in-pancreatic-cancer-treatment 2022-01-13T13:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/f550d369c49e8277/personalized-prediction-model-for-alzheimer-s-disease-progression-and-donepezil-treatment-effects 2022-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/01c1b3451e1fa75b/ideaya-biosciences-announces-corporate-and-portfolio-updates-at-j-p-morgan-healthcare-conference 2022-01-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d85566e932acf52b/maze-therapeutics-announces-190-million-financing 2022-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5f3d2ff6af2b31e7/ascendis-pharma-a-s-updates-on-vision-3x3-strategy-and-2022-milestones 2022-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/21abbcfbab63ef28/icecure-medical-ceo-highlights-2021-achievements-and-2022-objectives 2022-01-05T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f962058dbd865cb0/nice-rejects-astrazeneca-s-lynparza-for-prostate-cancer-despite-scottish-approval 2022-01-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6f9e5e7ee24bff18/safety-and-efficacy-of-aadc-gene-therapy-for-moderately-advanced-parkinson-disease-three-year-outcomes 2022-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4bebdc7e3c7e3507/research-ethics-board-approves-amendment-to-canadian-covid-19-treatment-trial-to-include-lsalt-peptide 2022-01-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/30d031e07f1cadb4/events-circulars-forms 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f6486b3022a86468/real-world-faricimab-namd-outcomes 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2fea23f2132b273f/a-multi-center-open-label-single-arm-trial-to-evaluate-the-efficacy 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/be3437b917989a6c/fruquintinib-granted-us-fda-fast-track-designation-for-metastatic-colorectal-cancer-treatment 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9a57ad316356ae47/teprotumumab-tepezza-approved-for-thyroid-eye-disease-treatment 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/06d7b15dfe0d2d55/limmatech-awarded-fda-fast-track-designation-for-vaccine-candidate 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8ac7a1f578c0d57e/hutchmed-announces-savolitinib-snda-accepted-in-china-for-nsclc-treatment 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d68e68270074be65/fda-approves-verrica-s-ycanth-first-treatment-for-molluscum-contagiosum 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f7c6c0960208bd06/treatment-of-multiple-sclerosis-related-trigeminal-neuralgia-with 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8b2c14bf29c2dd34/hutchmed-to-present-key-clinical-data-for-multiple-cancer-therapies-at-asco-2025 2022-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/63a8a8b7755e2513/decentralized-clinical-trials-show-promise-in-expanding-healthcare-access-and-diversity 2021-12-31T08:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/d22653cbb960bef3/mercury-biomed-awarded-1-5m-national-institutes-of-health-grant-ap-news 2021-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/30b8da6ac7a3f7d7/car-t-cell-therapy-shows-promise-in-treating-b-cell-lymphoma 2021-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/07203f8c25047267/real-world-assessment-of-patient-care-and-practice-efficiency-with-subcutaneous-rituximab 2021-12-22T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/461825135fd03dd7/insilico-medicine-initiates-first-in-human-study-of-ism001-055 2021-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c80c30c516e06e60/eu-approves-apellis-and-sobi-s-aspaveli-for-pnh-with-restricted-label 2021-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7bfcea43aa779e61/advances-in-parp-inhibitor-combinations-show-promise-for-ovarian-cancer-treatment 2021-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5a2ccf774b7eeafb/polatuzumab-vedotin-shows-superior-efficacy-in-first-line-dlbcl-treatment-and-confirms-long-term-benefits-in-relapsed-disease 2021-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d55e59e834363710/sentinel-lymph-node-biopsy-after-neoadjuvant-therapy-shows-promise-in-node-positive-breast-cancer-patients 2021-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1860ad01be3c0b06/als-drug-development-gains-momentum-with-new-research-approaches-and-industry-investment 2021-12-12T16:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/12af27da1ef7c8e3/samuraciclib-plus-fulvestrant-shows-promising-results-in-heavily-pretreated-hr-breast-cancer 2021-12-10T18:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/5f04154d4972badf/fda-approves-first-eye-drops-for-presbyopia-treatment-offering-alternative-to-reading-glasses 2021-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3d52541cfb82e437/zanidatamab-plus-chemotherapy-shows-promising-results-in-heavily-pretreated-her2-positive-breast-cancer 2021-12-09T17:45:15+00:00 weekly 0.7 https://trial.medpath.com/news/a3707602b9e194ee/anti-covid-19-drug-authorized-in-us-for-those-uneligible-for-vaccination 2021-12-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/59de61e9b0939833/gh-research-announces-successful-outcome-of-phase-2-clinical-trial-for-gh001-in-treatment-resistant-depression 2021-12-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3f04d6e6c716211a/fda-approves-insightec-s-exablate-neuro-for-advanced-parkinson-s-disease-treatment 2021-12-03T13:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/ce834272ce607e91/minocycline-extended-release-comparison-with-doxycycline-for-the-treatment-of-rosacea-a-randomized-head-to-head-clinical-trial-jcad-the-journal-of-clinical-and-aesthetic-dermatology 2021-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f1a481fb3553d94e/gene-therapy-for-duchenne-muscular-dystrophy-pmc 2021-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6127cd6020d630da/fda-grants-orphan-drug-designation-to-ct120-dual-targeted-car-t-therapy-for-acute-lymphoblastic-leukemia 2021-11-26T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/54a016cc6e75667d/real-world-evidence-increasingly-influences-fda-drug-approvals-study-finds 2021-11-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/23e2f71f6a432d8f/study-finds-escitalopram-reduces-adverse-effects-of-psilocybin-without-affecting-positive-mood-effects 2021-11-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4532bf3cc34c464d/global-summit-to-address-breakthrough-therapies-for-mitochondrial-diseases 2021-11-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dabc4cf4022be4ad/next-generation-kinase-inhibitors-summit-to-address-key-challenges-in-cancer-treatment-development 2021-11-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/81acdddebee24e52/discovery-expands-donor-pool-for-stem-cell-transplants-in-cancer-patients 2021-11-19T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6b57c2c993ea3019/chop-led-study-shows-novel-gene-therapy-for-hemophilia-a-leads-to-sustained-expression-of-clotting-factor-and-reduced-bleeding-events 2021-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e9bf6fe039e42c20/fasting-mimicking-diet-shows-promise-in-modulating-metabolism-and-enhancing-antitumor-immunity-in-cancer-patients 2021-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/08f16ef46aab4b6f/singapore-launches-project-golden-years-groundbreaking-qualitative-study-on-dementia-prevention-attitudes 2021-11-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aff42d02cc63f5e0/ema-grants-orphan-drug-designation-to-rafael 2021-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0e00994bb01fcca6/shorter-course-of-radiation-therapy-proves-safe-and-effective-for-post-surgery-prostate-cancer-patients 2021-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7e876ef638bc8bda/clarity-pharmaceuticals-completes-dosimetry-phase-of-sar-bispsma-theranostic-trial-for-metastatic-prostate-cancer 2021-11-10T09:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/4d46a14027b7104c/arbor-biotechnologies-secures-215m-series-b-to-advance-crispr-gene-editing-platform 2021-11-09T07:47:07+00:00 weekly 0.7 https://trial.medpath.com/news/c49a4ffdded613b4/scope-biosciences-secures-eur1m-investment-to-advance-crispr-based-diagnostic-platform 2021-11-08T17:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/7d47889dad7f48d4/hkbu-researchers-engineer-exosome-based-delivery-system-for-alzheimer-s-treatment-using-chinese-medicine-compound 2021-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/63e7ac61b2215daa/deepmind-launches-isomorphic-labs-to-transform-drug-discovery-through-ai-innovation 2021-11-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3276f071da4d9281/hpv-vaccine-shows-87-reduction-in-cervical-cancer-cases-in-landmark-english-study 2021-11-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a34c36381f540840/fda-approves-breakthrough-twice-yearly-hiv-prevention-drug-lenacapavir-with-nearly-100-efficacy 2021-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/db7494a873bdc412/repurposed-antiviral-drugs-for-covid-19-interim-who-solidarity 2021-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b6eb790c56af2276/fda-greenlights-novartis-first-in-class-therapy-for-cml-biospace 2021-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/da4fc49da324899c/cambridge-cognition-secures-major-contract-for-schizophrenia-trial 2021-10-26T13:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/7daf118b29e389ea/european-pharmaceutical-strategy-aims-to-strengthen-supply-chains-and-foster-innovation-post-covid 2021-10-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/487b147186337e5b/fda-approves-roche-s-susvimo-first-refillable-eye-implant-for-wet-amd-treatment 2021-10-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/deb57a4b7928dc87/half-dose-glucarpidase-as-efficient-rescue-for-toxic-methotrexate 2021-10-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/846e4db6d8266333/plus-therapeutics-receives-fda-clearance-for-186rnl-radiotherapy-trial-in-leptomeningeal-metastases 2021-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/48028f89db85496a/orphagen-pharmaceuticals-awarded-sbir-phase-ii-grant-to-develop-a-first-in-class-drug-for-adrenocortical-cancer-orphagen-pharmaceuticals 2021-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f56ddb5ebd23d9d5/covid-19-pandemic-catalyzes-major-transformation-in-global-regulatory-processes 2021-10-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fa3b651e4c962d2f/akadeum-life-sciences-secures-17-5m-series-b-to-advance-microbubble-based-cell-separation-technology 2021-10-12T13:48:37+00:00 weekly 0.7 https://trial.medpath.com/news/12587d0487c9fdd5/heparegenix-initiates-first-in-man-phase-1-trial-for-its-lead-mkk4 2021-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aefb08fc6130bb87/singapore-researchers-launch-clinical-trial-testing-novel-cell-state-conversion-approach-for-triple-negative-breast-cancer 2021-10-07T08:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/9cb71ebc772ef775/preliminary-data-on-225ac-j591-shows-promise-in-treating-mcrpc 2021-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c4f8a8495df92389/landmark-tosca-registry-reveals-new-insights-into-tuberous-sclerosis-complex-management 2021-10-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/09350acb4c065441/fda-approves-expansion-of-patient-enrolment-in-sequana-medical-s-poseidon-study-for-alfapump-treatment 2021-10-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9dc5b4556410a3ef/laboratory-safety-evaluation-of-bedinvetmab-a-canine-anti 2021-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4f57e58b2b90d6f8/acalabrutinib-venetoclax-and-obinutuzumab-as-frontline 2021-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/123d45a3b0d2fa9c/tempus-receives-first-fda-clearance-for-ai-based-atrial-fibrillation-risk-detection-algorithm 2021-09-27T19:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/7cea44f91d58990b/4th-rna-targeted-drug-discovery-summit-to-showcase-latest-advances-in-small-molecule-therapeutics 2021-09-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5acdb6fa39806276/breakthroughs-in-myocardial-infarction-treatment-new-drugs-on-the-horizon 2021-09-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a7e51012151bfb35/fore-biotherapeutics-highlights-recent-pipeline-achievements-and-strategic-objectives-for-2025 2021-09-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/26012f27810201c4/clinical-trials-loyal-for-dogs 2021-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6ff4812b0ea07c0a/helping-dogs-live-longer-healthier-lives-loyal 2021-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/177a6510f5768704/small-business-austin-daily-herald-austin-daily-herald 2021-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/397f9934b45ed237/pierre-fabre-advances-two-phase-ii-trials-of-encorafenib-in-chinese-patients-with-braf-v600e-mutations 2021-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/21f02e8bff392597/lung-cancer-patients-in-england-to-receive-breakthrough-drug-sotorasib-on-nhs 2021-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/56ed3db767f4571d/fda-approved-gout-medicine-could-also-battle-covid-19 2021-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/533673e810b4a1eb/nhs-pioneers-early-access-to-amgen-s-breakthrough-kras-lung-cancer-drug-lumykras 2021-09-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c10409e62d4909fa/meta-analysis-reveals-significant-efficacy-reporting-bias-in-car-t-cell-therapy-clinical-trials 2021-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eb3854e383153faf/acupuncture-for-combat-post-traumatic-stress-disorder-a-clinical-trial 2021-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c1d749c1fa50023a/blockchain-technology-poised-to-transform-healthcare-data-management-and-patient-privacy 2021-09-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d695b62e999778b0/a-new-and-validated-randomised-controlled-placebo 2021-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fccbb38e69fa6107/monoclonal-antibody-prevents-malaria-in-small-trial-nih-record 2021-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6229fe5627ed4912/fda-approves-zanubrutinib-for-waldenstrom-s-macroglobulinemia-treatment 2021-09-01T22:35:51+00:00 weekly 0.7 https://trial.medpath.com/news/c6d5824cf55ff47c/nci-and-cdisc-partnership-advances-clinical-trial-data-standardization-through-controlled-terminology 2021-08-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7f5b113af2bcfb41/device-therapy-in-chronic-heart-failure-jacc-state-of 2021-08-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b19ab5ac05347d52/debunking-external-control-arms-myths-new-frontiers-in-clinical-trial-design 2021-08-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/204b824310e9ff7c/nci-s-research-on-covid-19-vaccines-and-antibodies 2021-08-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ddab85ce7e68cb58/long-non-coding-rnas-emerge-as-key-regulators-of-vascular-endothelium-and-angiogenesis 2021-08-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b8ffae2f92bafa71/patient-centric-trial-design-boosts-recruitment-success-and-launch-probability-by-19 2021-08-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1a73ef26589fe8d0/fda-issues-safety-alert-on-unapproved-robot-assisted-mastectomy-procedures 2021-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2dedcf86a1cab6d8/uk-approves-first-covid-19-monoclonal-antibody-treatment-as-astrazeneca-reports-77-efficacy-in-prevention-trial 2021-08-20T13:43:59+00:00 weekly 0.7 https://trial.medpath.com/news/0194b7f49efe052f/ponatinib-dose-ranging-study-shows-efficacy-in-chronic-phase-cml-patients 2021-08-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/72a2c735a92621b6/dealing-with-breast-cancer-means-also-keeping-in-mind-heart-health 2021-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/50cf7d4326c953b2/ucb-announces-u-s-fda-approvals-for-bimzelx-r-bimekizumab-bkzx-for-the-treatment-of-psoriatic-arthritis-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis 2021-08-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c3f15855b1709130/seagen-secures-2-6b-deal-with-remegen-for-novel-her2-targeting-cancer-drug 2021-08-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/00912d7df397ab04/amazon-invests-14-7-million-in-proteome-analysis-company-nautilus-biotechnology 2021-08-05T18:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/0c88e706bc04eb6a/new-drug-combo-shows-early-potential-for-treating 2021-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d74dd59370156b15/watchdog-to-review-fda-s-approval-process-for-biogen-s-alzheimer-s-drug 2021-08-04T17:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/6b344b8942d68b98/luye-pharma-s-next-generation-vmat2-inhibitor-ly03015-to-begin-clinical-trials-in-the-u-s 2021-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/751c41024b098cbf/fda-grants-first-ever-breakthrough-device-status-to-digital-therapeutic-for-heart-failure-management 2021-08-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4a708cd6286bb83e/ascentage-pharma-announces-milestone-payment-from-unity-biotechnology-for-senolytic-drug-candidate-ubx1325 2021-07-28T23:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/893944884ca7d09c/minimal-residual-disease-in-myeloma 2021-07-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/12301c536b3dc02f/abbvie-and-calico-announce-second-extension-of-collaboration-focused-on-aging-and-age-related-diseases 2021-07-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cad01acd36c246c8/fda-approves-shingrix-for-shingles-prevention-in-immunocompromised-adults 2021-07-26T14:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/0d93eb7e6946a132/byheart-secures-90m-series-b-financing-and-achieves-all-of-its-clinical-trial-endpoints 2021-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a8f55a3d65218d71/patient-centric-approach-could-transform-unsustainable-oncology-r-d-landscape 2021-07-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1c7afa9ae9f388c1/seres-therapeutics-microbiome-drug-fails-phase-2-ulcerative-colitis-trial-casting-shadow-over-emerging-field 2021-07-22T11:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/58f1af5e2c3bcdeb/attention-sponsors-be-prepared-to-publish-your-interim-clinical-study-results 2021-07-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/94794ea1d882d7b9/psilera-partners-with-worldwide-for-accelerated-clinical-development-of-dmt-patch 2021-07-14T09:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/c3d45e57319180dd/fda-lifts-partial-clinical-hold-on-trial-examining-cdk8-cdk19-inhibitor-rvu120-in-aml-mds 2021-07-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d7bc2a761b9cf063/breakthrough-in-long-covid-detection-blood-test-could-be-available-within-6-12-months 2021-07-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3eeceac27c3831af/china-launches-patent-linkage-system-to-resolve-drug-patent-disputes-before-market-entry 2021-07-07T05:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/2248aff104b7574d/adjuvant-cdk4-6-inhibitors-combined-with-endocrine 2021-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ae09d09581db1d82/novel-nlrp3-inflammasome-inhibitors-show-promise-for-treating-multiple-inflammatory-diseases 2021-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/30625d1743fdeca9/iterum-stock-nosedives-as-fda-flags-deficiencies-in-sulopenem-application 2021-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3731fffa75fa2dbf/safety-and-pharmacokinetics-of-casimersen-in-duchenne-muscular-dystrophy-patients 2021-06-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/10939eba76232a39/fda-adds-heart-inflammation-warning-to-moderna-and-pfizer-covid-19-vaccine-fact-sheets 2021-06-26T02:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/f0d0d6fb65533b08/rapts-rpt193-in-atopic-dermatitis-drops-by-13-points 2021-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/de526b2796b39b35/advances-in-car-t-cell-therapy-for-non-hodgkin-lymphoma 2021-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1605650f80a2c778/philips-launches-define-gps-trial-to-evaluate-ifr-guided-pci-for-superior-outcomes 2021-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/757ca1f9f2b0b79b/agios-submits-new-drug-application-to-fda-for-mitapivat-for-treatment-of-adults-with-pyruvate-kinase-deficiency 2021-06-21T11:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/916b3c25891c9dae/ai-and-automation-set-to-transform-pharmaceutical-r-d-industry-faces-cultural-and-technical-hurdles 2021-06-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4b571ee3534fc925/fda-grants-breakthrough-therapy-designation-to-rusfertide-for-polycythemia-vera 2021-06-12T14:42:50+00:00 weekly 0.7 https://trial.medpath.com/news/f653dad8929b9d6c/3-experts-resign-from-fda-panel-over-alzheimer-s-drug-approval 2021-06-11T14:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/c258fd9eae38bb6e/phase-i-iia-clinical-trial-of-rh5-1-as01b-vaccine-for-blood-stage-malaria-shows-promising-safety-and-immunogenicity 2021-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ad79991d7bf33490/laparoscopic-radical-hysterectomy-vs-open-surgery-for-early-stage-cervical-cancer 2021-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b2bcf8e8116a226a/fda-approves-aduhelm-first-disease-modifying-alzheimer-s-treatment-in-nearly-two-decades 2021-06-07T15:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/a43f37e8e12058b5/fda-approved-and-emerging-biomarkers-transform-immune-checkpoint-inhibitor-patient-selection 2021-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d92f2d6e7f0c4ddd/newly-approved-drug-sotorasib-shows-promise-in-treating-lung-cancer-with-kras-mutation 2021-06-04T18:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/ba943df8c54bac4b/prognostic-value-of-measurable-residual-disease-monitoring-by-next 2021-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/90b3f615f0db00c9/first-in-human-study-of-pf-06647020-cofetuzumab-in-patients-with-advanced-solid-tumors 2021-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7e41ad3a474aa280/melanocortin-antagonists-emerge-as-promising-treatment-for-cancer-cachexia 2021-06-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/60eca46e9b712659/hybrytetm-a-promising-skin-directed-therapy-for-cutaneous-t-cell-lymphoma 2021-06-02T14:45:55+00:00 weekly 0.7 https://trial.medpath.com/news/3c81f25891585265/iterum-therapeutics-stock-shoots-higher-as-sulopenem-application-review-on-track 2021-05-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/edccc066a3221302/j-j-s-new-cancer-drug-leads-a-growing-pipeline-of-dual-targeting 2021-05-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0078d7afbbf0df02/lorlatinib-shows-promising-efficacy-in-alk-rearranged-nsclc-with-21-8-month-median-pfs 2021-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8a14d49e4b331cfa/first-time-drug-launches-mckinsey-data-shows-67-of-products-miss-sales-targets-despite-growing-market-share 2021-05-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8d85a908de4b3eae/alume-biosciences-granted-fda-fast-track-designation-of 2021-05-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4b9b119affad2bce/healthware-group-unveils-strategic-digital-health-roadmap-for-healthcare-industry-evolution 2021-05-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dd747dbd25d2d09f/atricure-afib-treatment-device-wins-fda-approval-massdevice 2021-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/744b8c1f280d842b/iza-bren-adc-achieves-100-response-rate-in-egfr-mutated-nsclc-when-combined-with-osimertinib 2021-04-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5a5c25db18b745ef/fda-approves-ventana-mmr-rxdx-panel-as-companion-diagnostic-for-dostarlimab-in-endometrial-cancer 2021-04-22T18:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/735a40e08831e0ff/rock2-inhibition-with-belumosudil-kd025-shows-promise-in-treating-chronic-graft-versus-host-disease 2021-04-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cbdaf04baeb90ff7/fda-grants-orphan-drug-status-to-novel-irak4-inhibitor-for-aml-and-mds-treatment 2021-04-19T20:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/ae57c0320f5ce344/fda-revokes-eua-for-monoclonal-antibody-therapy 2021-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/074e2f67b0309660/clinical-effectiveness-of-lyme-vaccine-a-matched-case-control 2021-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6ae402e971b49c6c/post-pandemic-launch-excellence-three-strategic-pillars-for-pharmaceutical-success 2021-04-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9dad80346d865c1a/spine-biopharma-initiates-phase-3-trial-for-first-in-class-intradiscal-treatment-of-chronic-low-back-pain 2021-04-15T14:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/5f8c6786c78de20e/car-t-cell-therapy-approved-for-multiple-myeloma 2021-04-14T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3cc34cf9e9ff615d/nccn-announces-projects-to-study-oral-decitabine-and-cedazuridine 2021-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/299f3ad559e5ff8b/bispecific-car-t-therapy-targeting-cd19-cd20-shows-promise-in-relapsed-b-cell-lymphoma 2021-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/624942cad5d6b6f9/mayo-clinic-study-links-car-t-cell-aging-to-cancer-relapse-in-largest-b-cell-lymphoma-analysis 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/673072735c6309b9/neoadjuvant-chemohormonal-therapy-before-radical-prostatectomy-for-high-risk-prostate-cancer 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4e2f276e07b2818a/pfizer-s-sasanlimab-bcg-combination-shows-significant-improvement-in-high-risk-bladder-cancer-trial 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1d31fe1457cb77f2/ema-grants-orphan-drug-designation-to-ict01-for-acute-myeloid-leukemia-treatment 2021-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dda1550b3abadb52/controversy-surrounds-fda-approval-of-pembrolizumab-for-high-tmb-solid-tumors 2021-04-08T15:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/8cf81a184e513258/prostate-specific-membrane-antigen-psma-targeted 2021-03-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/86d2a2296091f688/adr-that-result-in-revision-of-patient-information-2021-03-25-1 2021-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0c8a263f26dd8198/uk-pm-s-greed-comments-spark-controversy-amid-global-vaccine-distribution-debate 2021-03-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cb91161057e3e1db/gamification-emerges-as-powerful-tool-in-healthcare-from-patient-care-to-medical-education 2021-03-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2a3a1382dabf7337/cdk4-6-inhibitors-as-adjuvant-treatment-for-hormone-receptor-positive-her2-negative-early-breast-cancer-a-meta-analysis 2021-03-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/305349700c1e64db/savana-leverages-ai-to-transform-ehr-data-into-actionable-clinical-insights 2021-03-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bee41e1e4e306465/phase-3-trial-of-libtayo-r-cemiplimab-monotherapy-in-advanced-cervical-cancer-shows-significant-survival-benefit 2021-03-15T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9eafef3521abb8e1/advances-in-prognostication-and-treatment-of-polycythemia-vera-with-pegylated-interferon-and-mdm2-inhibition 2021-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4f85c06ee6900d7c/virtual-patient-engagement-reshapes-clinical-trial-design-post-covid 2021-03-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c3b403e047ff94fa/study-demonstrates-effectiveness-of-precision-biopsy-strategy-in-prostate-cancer-detection 2021-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4ae068c386417db0/mrna-covid-19-vaccines-achieve-historic-emergency-authorization-with-95-efficacy 2021-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8cfabf88e4c757ab/metastatic-patterns-and-treatment-response-in-prostate-cancer-new-insights-into-disease-progression 2021-03-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/edc4b0848dfb247d/lyme-prep-novel-monoclonal-antibody-treatment-enters-human-clinical-trials 2021-03-03T08:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/727c5a2a1a16c415/research-initiative-launches-to-address-mental-health-crisis-in-rare-disease-diagnoses 2021-02-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7060c9ee04877dc9/breakthrough-gene-therapy-eliminates-need-for-enzyme-replacement-in-fabry-disease-patients 2021-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/237ddcf0d3cdaa2e/new-video-resource-highlights-critical-insights-from-rare-disease-patient-community 2021-02-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6a29f17d51f53a09/off-the-shelf-nk-immunotherapy-shows-promise-in-b-cell-nhl-treatment 2021-02-19T17:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/d3850bc5f7b477b3/a-reflection-on-the-covid-19-vaccine 2021-02-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aafb5124814e7a66/grunenthal-leaders-outline-four-key-principles-for-future-pharmaceutical-marketing-in-post-covid-era 2021-02-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/00c064e3cfa347ba/semaglutide-shows-unprecedented-weight-loss-results-in-major-international-trial 2021-02-11T21:22:27+00:00 weekly 0.7 https://trial.medpath.com/news/d24f061c05ca5bc7/ipsen-advances-neurotoxin-research-for-spasticity-treatment-aims-to-develop-longer-acting-therapies 2021-02-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/75f84e6674273078/heart-disease-devices-lead-latest-batch-of-fda-breakthrough-nods 2021-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ec21deabc9d9e76e/fda-approves-prucalopride-for-chronic-idiopathic-constipation 2021-02-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4ff7535c8c10a519/jazz-pharmaceuticals-acquires-gw-pharma-in-7-2b-cannabis-medicine-deal 2021-02-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abd752aa32cdecbe/disease-rarity-and-clinical-benefits-drive-rare-disease-drug-pricing-in-germany-s-amnog-system 2021-02-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/624f80aebad57af4/bms-seeks-fda-approval-for-zeposia-in-ulcerative-colitis-with-may-decision-date 2021-02-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3de006e81e844488/promising-results-for-ziresovir-in-treating-respiratory-syncytial-virus-in-infants 2021-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/48018f8218f3b71c/medtronic-receives-fda-approval-of-diamondtemp-ablation-system-for-the-treatment-of-patients-with-atrial-fibrillation 2021-01-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/004c42776c099ef9/sangamo-therapeutics-charts-pragmatic-course-in-gene-editing-evolution-balancing-innovation-with-viability 2021-01-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/845ce4cf6bbecf95/us-biosimilar-market-set-for-100-billion-cost-reduction-as-adoption-accelerates 2021-01-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eb4b0fb1a1bc93b6/rising-liver-cancer-cases-in-the-us-linked-to-alcohol-associated-liver-disease-and-masld 2021-01-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1caa9c66e8ac70e9/addressing-the-trust-crisis-in-clinical-trials-lessons-from-historical-cases-to-modern-solutions 2021-01-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b4bc2f82e3bec42c/fda-breakthrough-device-designation-granted-for 2021-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/00d34cab622747fc/leading-biotech-companies-converge-at-mitochondria-targeted-drug-development-summit-to-advance-therapeutic-pipeline 2021-01-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/64bac04d1fc1a5ae/five-year-outcomes-from-the-randomized-phase-iii-trials-nivolumab-versus-docetaxel-in-previously-treated-non-small-cell-lung-cancer 2021-01-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5ad499de91fdc00d/recurrent-gbm-brain-tumors-with-few-mutations-respond-best-to-immunotherapy 2021-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6d19820f6c7bb15f/uk-launches-new-pathways-for-accelerated-drug-access-and-evaluation-in-2021 2021-01-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/031963d6d9ad0a9d/bluebird-bio-announces-strategic-split-into-separate-gene-therapy-and-oncology-companies 2021-01-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f408d96ffc1aa488/fda-approves-novartis-scemblix-r-asciminib-with-novel-mechanism 2021-01-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c8f6a5046ebb083e/role-of-immunotherapy-in-bladder-cancer 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/99767a9e868c2b66/triplet-combination-of-durvalumab-tremelimumab-and 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/06ae414e61b7ae76/biomarkers-identified-for-camrelizumab-apatinib-combination-in-advanced-triple-negative-breast-cancer 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/337a7e7b280c5ebb/clinical-trial-design-during-and-beyond-the-pandemic 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2e66726cb11e3ce6/innovative-car-t-cell-and-oncolytic-virus-therapies-show-promise-in-treating-aggressive-cancers 2021-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/730c88f6b1f69bcc/rakuten-medical-acquires-critical-irdye-700dx-assets-from-li-cor-to-secure-photoimmunotherapy-supply-chain 2020-12-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6b41009534cbdeed/covid-19-pandemic-reshapes-patient-centric-clinical-trial-landscape-in-2020 2020-12-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d1739549b0f726a0/palforzia-a-new-hope-for-children-with-peanut-allergy 2020-12-21T12:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/abddc6ea04ad9eb8/interferon-alpha-shows-promise-in-reducing-myelofibrosis-risk-and-mortality-in-polycythemia-vera-patients 2020-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/11ef6a9102e7f8eb/dr-patnaik-on-activity-of-sl-401-in-chronic 2020-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/42b6d85ac2c217de/how-the-clinical-research-community-responded-to-the-covid-19 2020-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/84f27146c72ae62a/sglt2-inhibitors-show-promising-results-for-elderly-with-type-2-diabetes 2020-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9e8bbed41dd9b3c1/enhertu-nears-eu-approval-for-her2-positive-breast-cancer-treatment 2020-12-13T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/540347ec9c3aaea9/scottish-health-authority-rejects-daiichi-sankyo-s-novel-cholesterol-drug-nilemdo 2020-12-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/678e22b050bf6ff3/uniqure-announces-two-year-follow-up-data-from-the-phase-iib-study-of-etranacogene-dezaparvovec 2020-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b379246c5457e555/3030-preliminary-results-of-an-ongoing-phase-1-dose 2020-12-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/130859294e035e9c/navigating-latin-american-pharma-markets-challenges-and-opportunities-amid-regulatory-evolution 2020-12-06T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/df1cecbfca892215/mrna-vaccines-how-moderna-and-pfizer-biontech-revolutionized-covid-19-immunization 2020-12-05T18:35:42+00:00 weekly 0.7 https://trial.medpath.com/news/f91f90a906151966/reporting-and-design-of-randomized-controlled-trials-for-covid-19 2020-12-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/178eafbb42f54ecb/fda-grants-fast-track-designation-for-remestemcel-l-in-the-treatment-of 2020-12-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/189b230d8612c1c7/gout-drug-colchicine-to-be-tested-as-covid-19-treatment-daily-mail-online 2020-11-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5e9aec8b69848378/technological-advances-and-patient-partnerships-drive-new-era-in-rare-disease-drug-development 2020-11-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cb9bf79d36715399/significant-improvement-in-progression-free-survival-with-sarclisa-combination-therapy-for-previously-treated-multiple-myeloma 2020-11-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/75c720feebcf7b15/gilead-s-27-billion-oncology-transformation-strategic-deals-reshape-company-s-future 2020-11-23T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/21d554b872db0baf/integrated-cbti-and-pap-adherence-program-improves-sleep-and-pap-use-in-veterans-with-comorbid-insomnia-and-osa 2020-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3770f8c742ad0f1f/havas-health-you-launches-global-research-initiative-to-track-healthcare-evolution-post-covid 2020-11-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a6afc82b4452033c/cyclarity-launches-human-trial-for-atherosclerosis 2020-11-19T08:40:44+00:00 weekly 0.7 https://trial.medpath.com/news/e72d31b4fefed6fb/nihr-and-pfizer-launch-initiative-to-enhance-patient-engagement-in-uk-clinical-trials-design 2020-11-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/729126c02b89b640/ema-committee-backs-roche-s-phesgo-a-novel-subcutaneous-combination-of-herceptin-and-perjeta-for-her2-breast-cancer 2020-11-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7ed12b88e705553a/fda-approves-blincyto-r-blinatumomab-in 2020-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f09ed9af7c2a9f44/fda-grants-fast-track-designation-to-panitumumab-for-metastatic-colorectal-cancer-treatment 2020-11-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b32d0aa9487d77e/fda-just-authorized-a-breakthrough-coronavirus-drug-thats-proven-to-save-lives 2020-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1173b0e958544285/prestige-biopharma-partners-with-teva-israel-for-trastuzumab-biosimilar-commercialization 2020-11-10T22:48:49+00:00 weekly 0.7 https://trial.medpath.com/news/153a9feb2c6dc07b/exscientia-strengthens-ai-drug-discovery-leadership-with-astrazeneca-veteran-as-new-cto 2020-11-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0ac0dd8d696b6efe/subcutaneous-isatuximab-plus-pd-shows-promise-in-r-r-multiple-myeloma-treatment 2020-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fa5ac6f1bc1d0bd2/liso-cel-plus-ibrutinib-shows-promise-in-relapsed-refractory-cll-sll-primary-results-from-transcend-cll-004-study 2020-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f5b9f056fb55ceda/exploring-new-frontiers-in-non-small-cell-lung-cancer-treatment 2020-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/15aa3f678bed5064/exploring-immunotherapy-as-a-potential-treatment-for-penile-cancer 2020-11-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/631447d7b2025220/psma-pet-ct-accurately-detects-prostate-cancer-spread 2020-11-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2c748aee2699e267/updated-safety-and-efficacy-results-from-a-phase-2-study-of 2020-11-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7af6f6a0748608bd/phase-3-destiny-breast05-trial-compares-trastuzumab-deruxtecan-to-t-dm1-in-high-risk-her2-early-breast-cancer 2020-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/74faa4709736807e/ring-20-syndrome-ultra-rare-epilepsy-faces-diagnostic-challenges-in-era-of-modern-gene-sequencing 2020-11-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/be16a1adec1ee027/inavolisib-combination-significantly-improves-survival-in-pik3ca-mutant-advanced-breast-cancer 2020-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b3e3e1289e6df46e/the-worldwide-clinical-trial-research-response-to-the-covid-19 2020-10-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/15e700b40f3ae9c3/university-of-minnesota-trial-shows-hydroxychloroquine-does-not-prevent-covid-19-in-high-risk-health-care-workers 2020-10-21T10:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/1c13411910463560/update-iterum-therapeutics-to-present-data-from-phase-3-trials-in-uncomplicated-and-complicated-urinary-tract-infections-at-idweek-2020-nasdaq-itrm-menafn-com 2020-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8857438fdc99375e/lrrc15-antibody-drug-conjugates-show-promise-as 2020-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a159149f9c09989a/2020nian-10yue-hesi-2 2020-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d03db8c22f217a37/poly-adp-ribose-polymerase-parp-inhibitor-regimens 2020-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/49d41aef8dfd7517/clinical-trial-automation-a-game-changing-solution-for-accelerating-drug-development 2020-09-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/63a4d157abc68d46/comprehensive-analysis-of-clinical-trials-in-pancreatic-cancer-reveals-limited-advances 2020-09-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3102210c178977d8/immunotherapy-improves-survival-in-advanced-bladder-cancer-patients 2020-09-19T11:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/5a2466d8bf104554/fda-approves-new-first-line-treatment-for-head-and-neck-cancers 2020-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b373e457ac0ad63c/increased-risk-of-diabetic-ketoacidosis-with-sotagliflozin-in-type-1-diabetes-patients 2020-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fc2cf026844f147e/genomic-medicine-evolution-bridging-the-gap-between-promise-and-clinical-reality 2020-09-13T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/92b375444292a947/crinetics-pharmaceuticals-announces-key-developments-and-appointments 2020-09-11T10:46:53+00:00 weekly 0.7 https://trial.medpath.com/news/0f251c4248f14e3b/pre-filled-syringes-conference-2021-to-address-key-innovations-in-injectable-drug-delivery 2020-09-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/537ef6626dfa4747/recruitment-into-the-alzheimer-prevention-trials-apt 2020-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bc4190d778d9c9fd/evolution-of-pharmaceutical-industry-from-apothecaries-to-modern-drug-development-giants 2020-08-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6d23667e61aec212/rna-targeted-drug-discovery-summit-to-address-key-challenges-in-small-molecule-development 2020-08-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6a670c08dac649ba/phase-3-trial-shows-low-dose-carbetocin-effective-for-hyperphagia-in-prader-willi-syndrome 2020-08-21T11:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/67f7c19847f16af8/nhs-embraces-telemedicine-revolution-71-of-gp-consultations-now-delivered-remotely 2020-08-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a91a7f6477175d6d/izotropic-files-pre-submission-application-with-u-s-fda-for-breast-ct-imaging-system 2020-08-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c315cf25e8232a70/first-line-nivolumab-plus-ipilimumab-shows-activity-in-msi 2020-08-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/90c68db1712279d2/ultrasound-guided-lung-recruitment-manoeuvre-shows-promise-in-reducing-postoperative-atelectasis-in-children 2020-08-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5062e71799719433/fda-approves-roche-s-evrysdi-a-more-affordable-oral-treatment-for-spinal-muscular-atrophy 2020-08-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2fc1992d4e0cf518/fda-approves-monjuvi-in-combination-with-lenalidomide-for-relapsed-refractory-dlbcl 2020-08-01T00:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/c8ad98adbf83d733/astrazeneca-and-daiichi-sankyo-form-6-billion-partnership-for-novel-trop2-targeting-cancer-drug 2020-07-26T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bc9bbf4bad01219c/fda-grants-fast-track-designation-for-abenacianine-in-lung-cancer-surgery 2020-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4763bfbc468fe346/advances-and-challenges-in-gynecologic-cancer-treatment 2020-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a5898e1e74f4aa14/racial-disparities-in-clinical-trials-african-americans-severely-underrepresented-in-multiple-myeloma-research 2020-07-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/470eb0907f981dfd/palliative-care-in-advanced-dementia-key-challenges-and-best-practices 2020-07-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8ad1b7e6e3fe63a3/fedratinib-a-newly-approved-treatment-for-patients-with 2020-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/178e5b0ea61f5ae3/tofersen-shows-promise-in-phase-1-2-trial-for-inherited-form-of-als 2020-07-08T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a7c7f9c187a3e6c3/novartis-agrees-to-678m-settlement-over-doctor-kickback-scheme-in-us 2020-07-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8d0ac065a9c2c73e/butantan-dv-dengue-vaccine-shows-promising-safety-and-immunogenicity-in-phase-2-trial 2020-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d7c42de6f141a86a/fda-rejects-intercept-s-nash-drug-obeticholic-acid-raising-industry-wide-concerns 2020-06-29T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/71ea4947f0599c02/efficacy-and-safety-of-zihua-wenfei-granules-in-treating-postinfectious-cough 2020-06-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f29ec65930eda7e2/advancements-in-ophthalmology-from-glaucoma-treatment-to-clinical-trials 2020-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0e96fdb67d34e1ca/sequana-medical-s-alfapump-mosaic-study-results-published-in-liver-transplantation 2020-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f26e978240ff16cd/immunotherapy-timing-crucial-for-advanced-bladder-cancer-treatment 2020-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/50487639c2da105f/global-pricing-dilemma-the-complex-challenge-of-valuing-covid-19-vaccines 2020-06-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c85bde459c674544/overcoming-osimertinib-resistance-in-egfr-mutant-nsclc-through-gsk-3-inhibition 2020-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7709e9b1bfc9f274/selinexor-is-an-oral-selective-inhibitor-of-nuclear-export 2020-06-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4f917465aafd6ec4/university-of-minnesota-trial-finds-hydroxychloroquine-no-better-than-placebo-in-preventing-covid-19 2020-06-03T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6ac9aad6f08a7036/advancements-in-neurology-from-hunter-syndrome-to-alzheimer-s-disease 2020-05-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d0a1cca25ce23bce/ftc-clears-abbvie-s-63-billion-allergan-acquisition-with-asset-divestiture-requirements 2020-05-06T09:53:40+00:00 weekly 0.7 https://trial.medpath.com/news/62f3062ac2e4abd4/a-single-arm-prospective-exploratory-study-to 2020-05-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d2bbc5c04da044f1/fda-accepts-nda-for-oral-semaglutide-25-mg-for-weight-management-and-cardiovascular-risk-reduction 2020-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/118da38038036d5f/global-clinical-trial-landscape-adapts-to-post-pandemic-research-challenges 2020-05-01T05:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/0d60129f6a766763/laboratory-of-malaria-immunology-and-vaccinology 2020-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0b33fc2196c656db/former-gsk-ceo-sir-andrew-witty-appointed-to-lead-who-s-global-covid-19-vaccine-initiative 2020-04-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/551f8f1cebcacf80/gene-therapy-shows-promise-in-treating-severe-b-thalassemia 2020-04-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1cc97178eb04f6a1/cuhk-study-finds-earlier-endoscopy-did-not-reduce-mortality-in-acute-upper-gi-bleeding 2020-04-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c4fefc6aaa2a485d/prisym-id-launches-validated-saas-platform-to-accelerate-covid-19-clinical-trial-labeling 2020-04-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/00b6d0d7246e18fc/first-crispr-therapy-dosed-nature-biotechnology 2020-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bd77e6eb38b97de0/combination-cyclin-dependent-kinase-4-6-inhibitors-and-endocrine 2020-04-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7bb877555a683db6/ai-revolutionizes-cancer-detection-breakthroughs-in-liquid-biopsies-imaging-and-pathology 2020-04-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/71bff3dfb58bd64c/cardiol-therapeutics-cannabidiol-formulation-shows-cardioprotective-effects-in-heart-failure-model 2020-04-01T11:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/e42280c05f8597a0/long-term-benefits-of-dose-dense-adjuvant-chemotherapy-in-early-breast-cancer-patients 2020-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/15882bde60f4386d/phase-ii-multi-center-open-label-single-arm-clinical-trial 2020-03-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f1dc57775878f099/five-key-strategies-for-enhancing-patient-centric-clinical-trials-amid-low-recruitment-rates 2020-03-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8acb2a2d1eddca8a/china-greenlights-clinical-testing-of-first-vaccine-against-covid-19 2020-03-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1778e04cbdb4185c/roche-s-vabysmo-demonstrates-sustained-efficacy-in-retinal-vein-occlusion-with-extended-dosing-intervals 2020-03-12T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/636e5c6eb0819d39/free-genetic-testing-initiative-accelerates-drug-development-for-inherited-retinal-diseases 2020-03-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/75f27d153a20853f/aptoll-novel-aptamer-based-therapy-shows-promise-for-acute-ischemic-stroke-treatment 2020-03-10T16:01:51+00:00 weekly 0.7 https://trial.medpath.com/news/00d205c447675d03/trial-of-sodium-phenylbutyrate-taurursodiol-for 2020-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/34110027ba74f37b/christie-hospital-launches-initiative-to-boost-cancer-trial-access-and-diversity 2020-03-08T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/584ae507b5deb57a/real-world-evidence-gains-momentum-fda-approvals-and-cross-industry-collaborations-mark-turning-point 2020-03-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d9723af9e6326679/clinical-trials-evolution-new-data-management-and-design-approaches-set-to-transform-drug-development-in-2020 2020-03-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e68e8e7ccdba5d40/novel-neural-biomarker-erna-shows-promise-for-optimizing-parkinson-s-disease-deep-brain-stimulation 2020-02-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/27c83cc67ae847b6/rare-disease-drug-development-faces-complex-challenges-despite-growing-pipeline 2020-02-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fdc0dc25272a6faa/psychedelics-and-psychedelic-assisted-psychotherapy-a-review-of-clinical-applications 2020-02-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/109f1cdb33f219fc/roche-and-bicycle-therapeutics-forge-1-7b-cancer-immunotherapy-alliance 2020-02-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2fc8c449f0f5d37d/u-s-health-officials-start-first-clinical-trial-with-gilead-sciences-experimental-coronavirus-treatment-themotleyfool-stocks-gild 2020-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/be653c85ccd11f31/federal-judge-rules-clinical-trial-sponsors-must-publish-a-decades-worth-of-missing-data 2020-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b94c688e2c9ee808/vifor-pharma-and-fresenius-kabi-form-strategic-alliance-to-address-iron-deficiency-in-china 2020-02-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/488759d89d39a281/digital-technologies-poised-to-reverse-declining-roi-in-pharmaceutical-r-d 2020-02-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0087d6b0362d9596/advancements-and-trials-in-cancer-treatment-highlighted-in-recent-studies 2020-02-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/94af69ce0fe7fed7/bd-completes-50-subject-clinical-trial-for-libertas-wearable-injector-system 2020-02-14T14:47:02+00:00 weekly 0.7 https://trial.medpath.com/news/840558dc24c15038/verona-pharma-announces-publication-of-key-phase-2b 2020-02-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0e46c3973472eacf/chinese-cdc-initiates-animal-testing-for-novel-coronavirus-mrna-vaccine 2020-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/49716c5b5049c539/j-j-hit-with-187m-punitive-damages-in-landmark-talc-cancer-trial 2020-02-06T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2ca2c9ea071ce33e/chinese-institute-files-patent-application-for-gilead-s-remdesivir-in-coronavirus-treatment 2020-02-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b33efdfe2ba88e36/immunology-market-evolution-interleukin-inhibitors-rise-as-biosimilars-reshape-treatment-landscape 2020-02-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b39eb59a1e2ab4a5/poly-adp-ribose-polymerase-parp-inhibitor-regimens 2020-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/82edd191ddfd9e46/4sc-resminostat-and-resmain-study-update-4sc-ag 2020-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/71fd8812ed9b4da7/us-biosimilar-market-reaches-critical-milestone-key-learnings-from-5-years-of-growth 2020-01-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/df52bd658cb673ad/psychedelic-drug-therapy-may-address-mental-health-concerns-in-people 2020-01-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/20dbd18005ea0062/nice-declines-nhs-coverage-of-spravato-for-treatment-resistant-depression-citing-cost-and-clinical-concerns 2020-01-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3237716dc18e7944/global-lung-ambition-alliance-takes-aim-at-three-major-challenges-in-lung-cancer-care 2020-01-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0addc1a3a5514db7/fda-and-nih-let-clinical-trial-sponsors-keep-results-secret-investigation-shows 2020-01-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f62566a4958f942c/cytokinetics-unveils-vision-2025-and-2020-corporate-milestones 2020-01-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/485fe502c5380888/mrd-monitoring-before-and-after-allo-hsct-predicts-outcomes-aml-hub 2020-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2622e1ebcff4038c/blood-brain-barrier-breakthrough-novel-delivery-system-shows-promise-for-brain-disease-treatment 2020-01-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c6d6b41b03e0ae5d/record-attendance-at-san-antonio-breast-cancer-symposium-2024 2020-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/159b310d4372d826/movement-of-poly-adp-ribose-parp-inhibition-into-frontline-treatment 2020-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/650eb6638636b552/minimal-residual-disease-status-as-a-surrogate-endpoint 2020-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b7f948a2d81bffc/exploring-anti-pd-l1-atezolizumab-as-an-immune-primer-and-concurrent-treatment-with-chemoradiotherapy-for-locally-advanced-cervical-cancer 2019-12-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4b92ae09183b0040/fda-unveils-historic-drug-import-plan-from-canada-to-combat-high-us-prices 2019-12-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b58b190a602d66c4/biogen-s-alzheimer-s-drug-in-spotlight-following-sarepta-s-vyondys-53-approval 2019-12-13T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bdbc4944caaaaef8/pertuzumab-regimen-shows-modest-survival-benefit-in-her2-positive-early-breast-cancer 2019-12-12T01:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/9625f12d52bfb387/sanofi-pivots-r-d-strategy-discontinues-diabetes-research-to-focus-on-novel-therapeutics 2019-12-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/98587578b233c0eb/tech-enabled-solutions-target-racial-disparities-in-clinical-trial-participation 2019-11-20T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/010373a70a267758/uk-nhs-progress-trial-shows-95-of-patients-carry-genetic-variants-affecting-drug-metabolism 2019-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/85182be4d11b931d/early-disease-screening-programs-show-significant-impact-on-chronic-disease-prevention 2019-11-15T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/275079bbf59d47a4/apple-launches-research-app-with-three-major-health-studies-focusing-on-women-s-health-heart-disease-and-hearing 2019-11-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f45169603611b88d/tufts-researchers-develop-light-activated-insulin-production-system-for-diabetes-treatment 2019-11-08T20:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/f4dd3be694fe117b/european-regulators-approve-lenacapavir-first-twice-yearly-hiv-prevention-injection 2019-11-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ad71193549828acd/china-grants-conditional-approval-to-seaweed-derived-alzheimer-s-drug-oligomannate 2019-11-04T19:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/b36d9b1e97e394bc/cyclin-dependent-kinase-4-6-inhibitor-in-combination-with-endocrine 2019-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/48fb03f16773cf80/eu-approves-astellas-xospata-for-flt3-positive-aml-showing-survival-benefit-over-chemotherapy 2019-10-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f8f11c056ecf8cc3/replimune-enrolls-first-patient-in-phase-1-clinical-trial-of-rp2-for-advanced-cancer 2019-10-24T12:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/d505a5b61e0b6ac9/nih-launches-influenza-human-challenge-study-to-advance-vaccine-development 2019-10-23T15:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/a1cb5cb0317c4f47/the-treatt-trial-evaluating-tranexamic-acid-in-haematological-malignancies 2019-10-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ceeaba1cf6a94e7e/final-analysis-from-resonate-up-to-six-years-of-follow-up-on-ibrutinib-vs-ofatumumab-in-cll 2019-10-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/df61046dee24511e/no-clinically-relevant-differences-in-qol-and-neurocognitive-function-with-lomustine-temozolomide-for-glioblastoma 2019-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6bfd3c70df419d36/minimal-residual-disease-status-as-a-surrogate-endpoint 2019-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f4258912bcdadcb6/focused-ultrasound-successfully-opens-blood-brain-barrier-in-als-patients-groundbreaking-trial-results 2019-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2a0115507edfaca7/small-clinical-trial-shows-drug-cocktail-reverses-biological-age-by-2-5-years 2019-09-10T19:56:06+00:00 weekly 0.7 https://trial.medpath.com/news/e2ce0c324bf603f1/clinical-trial-retention-crisis-30-dropout-rate-costs-industry-billions-and-delays-drug-development 2019-09-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/395688554619e8b6/minimal-residual-disease-status-as-a-surrogate-endpoint-for-pubmed 2019-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/963841c48043ab20/doxycycline-prophylaxis-for-bacterial-sexually-transmitted 2019-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/81d6bc1acb043f7d/four-drug-polypill-reduces-heart-attack-and-stroke-risk-by-34-in-landmark-trial 2019-08-23T00:17:18+00:00 weekly 0.7 https://trial.medpath.com/news/2d56d45eecafd4a7/rna-targeted-drug-discovery-summit-to-explore-breakthrough-small-molecule-therapeutics 2019-08-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ff39969bffb04ea4/eptinezumab-shows-promise-in-preventing-chronic-migraine 2019-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/12d92c0a22fef16b/roche-s-tecentriq-combination-shows-promise-in-advanced-bladder-cancer-phase-iii-trial 2019-08-05T09:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/fa839ffc0211d492/fda-approves-pexidartinib-as-first-treatment-for-tenosynovial-giant-cell-tumour 2019-08-04T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f948c7489b7d5a66/phase-ii-trial-of-the-glycoprotein-non-metastatic-b-targeted 2019-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0813730d926d8b91/genentech-expands-drug-discovery-portfolio-with-three-strategic-platform-partnerships 2019-07-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ead42797f26958a9/fda-approves-merck-s-recarbrio-for-complex-infections-with-antimicrobial-stewardship-focus 2019-07-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9039e7d649edb580/medidata-ceo-outlines-vision-for-clinical-trial-evolution-balancing-innovation-with-regulatory-compliance 2019-07-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/81034ad23a59570a/alder-biopharmaceuticals-presents-new-data-on-eptinezumab-s-clinical-profile-for-migraine-prevention 2019-07-12T02:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/8e1b9aa13923a1f1/clinical-and-radiographic-evaluation-of-biodentine-in-revascularization-of-non-vital-immature-teeth 2019-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ce71de05850a73e5/astrazeneca-appeals-nice-rejection-of-tagrisso-for-first-line-nsclc-treatment 2019-07-08T11:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/4a7bfadca129f7ba/feasibility-of-monitoring-compliance-with-intermittent-occlusion-therapy-glasses-for-amblyopia-treatment 2019-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/844479a96e645258/real-world-evidence-transforms-drug-development-fda-embraces-new-paradigm-in-clinical-research 2019-06-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d0b1a628b0b38478/denali-s-hunter-syndrome-candidate-receives-fda-orphan-drug-and-rare-pediatric-disease-designations 2019-06-12T14:30:02+00:00 weekly 0.7 https://trial.medpath.com/news/3d41b10eec334ffc/smi-s-9th-annual-orphan-drugs-conference-to-address-key-challenges-in-rare-disease-treatment-access 2019-06-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/73f88f311dbe6af9/sequana-medical-receives-fda-approval-for-alfapump-device-trial 2019-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/07b6df9f7be7fe03/immunotherapy-drug-shows-potential-to-cure-advanced-lung-cancer 2019-05-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bf01e433a7a4da04/novartis-receives-patent-for-novel-nlrp3-inflammasome-inhibitors-with-potential-for-multiple-inflammatory-diseases 2019-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/004efcaba3de07f6/leading-pharma-companies-unite-at-social-media-conference-to-share-digital-innovation-strategies 2019-05-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/79d8f938a5a735bf/fda-expands-real-world-evidence-framework-to-accelerate-drug-approvals-and-support-regulatory-decisions 2019-05-10T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2d0a4e9c2a19d826/uniqure-announces-updated-clinical-data-from-phase-iib-study-of-amt-061-in-hemophilia-b-patients 2019-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2207122c73bd7c57/fda-accepts-ionis-pharmaceuticals-nda-for-donidalorsen-as-prophylactic-treatment-for-hae 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ab8ef2b78e0a357d/neurosense-advances-als-treatment-with-primec-through-strategic-partnership 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d73c587585bc53b5/fda-grants-breakthrough-therapy-designation-for-gsk-s-osteosarcoma-treatment 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/16cd625880948367/vir-biotechnology-s-tobevibart-and-elebsiran-receive-fda-and-ema-designations-for-chronic-hepatitis-delta-treatment 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4f05d1337f9e5f63/fda-grants-rmat-designation-to-mesoblast-s-revascor-for-pediatric-hypoplastic-left-heart-syndrome 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1e3fd95d13793b94/rapport-therapeutics-prepares-to-report-phase-iia-epilepsy-trial-results-for-rap-219 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4e208dd1f51c7615/fda-approves-henlius-organon-denosumab-biosimilars-bildyos-and-bilprevda-for-bone-health-conditions 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9eae4c128ac77dd3/zealand-pharma-announces-first-participant-enrolled-in-zupreme-1-phase-2b-trial 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/907e5a615737a164/remegen-s-telitacicept-achieves-55-proteinuria-reduction-in-phase-3-iga-nephropathy-trial 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/21118d30fff308fa/astrazeneca-s-tagrisso-combination-therapy-extends-survival-to-nearly-four-years-in-advanced-lung-cancer 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c4bf86e78b9238a0/fda-issues-complete-response-letter-for-telix-s-kidney-cancer-imaging-agent-tlx250-cdx 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/954d6d1dbb340264/roche-receives-fda-and-ce-ivdr-approvals-for-expanded-her2-diagnostic-applications-in-cancer-treatment 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a224dcc2193dd622/cytomed-soars-on-research-deal-with-sunact-cancer-institute-for-solid-tumor-treatment-trial-in-india 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/02198e48804bc372/genentech-s-phase-iib-study-of-prasinezumab-in-early-stage-parkinson-s-disease-misses-primary-goal 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2a07ea75a51995df/nih-study-finds-siga-s-tecovirimat-did-not-improve-mpox-resolution-or-pain 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7d37e873bd79b985/precigen-receives-fda-approval-for-papzimeos-first-treatment-for-recurrent-respiratory-papillomatosis 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abfc6db71a9c8842/biontech-s-cancer-drug-trastuzumab-pamirtecan-meets-primary-endpoint-in-phase-3-breast-cancer-trial 2019-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/05ac288972e7800a/hybrytetm-a-promising-photodynamic-therapy-for-cutaneous-t-cell-lymphoma-ctcl 2019-05-01T15:53:39+00:00 weekly 0.7 https://trial.medpath.com/news/4e98ab3ef1e360b4/gene-therapy-breakthrough-effectively-cures-bubble-boy-disease-in-infants 2019-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fd9d3a9863b16a63/qgel-s-synthetic-matrix-breakthrough-aims-to-revolutionize-organoid-based-precision-medicine 2019-04-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e6f0e74d32c39ce6/overview-of-advanced-therapy-medicinal-products-atmps-in-the-european-union 2019-04-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f9e02f87ab8dd734/patient-centric-websites-and-plain-language-key-to-boosting-clinical-trial-recruitment 2019-04-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/88213d7169555b6e/astrazeneca-and-daiichi-sankyo-partner-in-6-9b-deal-for-novel-her2-targeting-cancer-drug 2019-03-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd92a6edf1d641d2/feasibility-pilot-trial-on-first-pass-intubation-success-rates 2019-03-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1bf6efd5d4ffda4e/fgfr1-overexpression-identified-as-a-key-resistance-mechanism-to-cdk4-6-inhibitors-in-er-breast-cancer 2019-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dc8167ca56b5e9d9/merck-kgaa-partners-with-iktos-to-accelerate-drug-discovery-through-ai-powered-molecular-design 2019-03-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/60abcb838df08b36/brainstorm-announces-first-patient-in-phase-2-clinical-trial-for-progressive-ms 2019-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/60bc27599e421b7d/innovations-and-trials-in-medical-technology 2019-03-12T14:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/736f38578859ccff/expanding-cancer-clinical-trial-eligibility-to-include-more-patients 2019-03-07T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/56ebc2ecc29b9e6a/fda-approves-resmetirom-rezdiffra-for-treating-mash-and-associated-fibrosis 2019-02-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d44e525f16085995/alteogen-secures-process-patent-for-aflibercept-biosimilar-claims-competitive-advantage 2019-01-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b02ceb3bd9b7baa0/ohsu-researchers-develop-promising-long-lasting-malaria-vaccine-using-novel-viral-platform 2019-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/23f54d64738f8c23/fda-approves-ontruzant-samsung-bioepis-and-merck-s-biosimilar-to-herceptin-for-cancer-treatment 2019-01-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8f8743643105e425/novel-liquid-biopsy-system-shows-promise-in-preventing-cancer-metastasis 2019-01-10T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5b6d3b2ea9ee738a/new-study-explores-treatment-for-hot-flashes-in-women-with-hr-positive-breast-cancer 2019-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5b9ca6b7e33a3c5b/mallinckrodt-s-specgx-llc-receives-fda-complete-response-letter-for-abuse-deterrent-immediate-release-reformulation-of-roxicodone-r-oxycodone-hydrochloride 2018-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/df4004d89d3a338f/new-fox-chase-trial-tests-risk-adapted-approach 2018-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6d05a8e468178c37/uk-unveils-new-five-year-drug-pricing-agreement-to-accelerate-nhs-medicine-access 2018-11-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9823d647b6485c73/fda-approves-first-treatment-for-primary-hemophagocytic-lymphohistiocytosis-marking-24-year-breakthrough 2018-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/92c160857e688d37/frontline-bortezomib-rituximab-cyclophosphamide 2018-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9d6e0107232446ff/fda-approves-first-direct-to-consumer-pharmacogenetic-test-from-23andme 2018-11-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/23838a597e108040/novartis-launches-biome-innovation-lab-network-to-accelerate-digital-health-solutions 2018-10-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/69e55a431c5d1d11/pfizer-strengthens-digital-strategy-with-new-chief-digital-officer-appointment 2018-10-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bf2bee36d8d19317/fda-launches-cybersecurity-playbook-to-protect-medical-devices-from-digital-threats 2018-10-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/061589e4244bcdad/j-j-s-continuous-manufacturing-journey-pioneering-success-with-hiv-drug-prezista 2018-09-24T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/770c22e8eeebaa75/survey-reveals-gap-between-patient-centric-aspirations-and-implementation-in-pharma-industry 2018-09-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cf1cfdd1d17d0452/life-molecular-imaging-secures-fda-fast-track-designation-for-18f-florbetaben-in-cardiac-amyloidosis-diagnosis 2018-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/66b800ea5664f873/eu-approves-sanofi-s-cablivi-as-first-targeted-therapy-for-rare-blood-clotting-disorder-attp 2018-09-02T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7edf8cc8b8e5af69/first-participants-randomized-in-askbio-phase-ii-gene-therapy-trial-for-parkinsons-disease 2018-08-27T14:25:15+00:00 weekly 0.7 https://trial.medpath.com/news/45124bac91d9ddc5/ai-revolutionizes-drug-discovery-major-tech-companies-and-startups-lead-innovation-wave 2018-08-21T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5b31310f030492ba/fda-grants-breakthrough-therapy-designation-to-novel-triplet-combination-for-braf-mutant-metastatic-colorectal-cancer 2018-08-07T19:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/03b8e8c255a612e2/boehringer-ingelheim-partners-with-uk-consortium-to-develop-novel-gene-therapy-for-cystic-fibrosis 2018-08-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7a9c2c9b69d24af0/oncolytic-virus-therapy-emerges-as-promising-cancer-treatment-breakthrough 2018-08-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/025e00920af97f75/low-dose-nivolumab-shows-promise-as-cost-effective-alternative-for-nsclc-treatment 2018-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5aeb865229cf618d/advancing-precision-medicine-with-synthetic-nearest-neighbors-in-clinical-trials 2018-08-01T00:00:00+00:00 weekly 0.7